EA017632B1 - Конденсированные гетероциклические соединения, полезные в качестве модуляторов киназы - Google Patents

Info

Publication number

EA017632B1

EA017632B1 EA200800873A EA200800873A EA017632B1 EA 017632 B1 EA017632 B1 EA 017632B1 EA 200800873 A EA200800873 A EA 200800873A EA 200800873 A EA200800873 A EA 200800873A EA 017632 B1 EA017632 B1 EA 017632B1

Authority

EA

Eurasian Patent Office

Prior art keywords

aminocyclohexyl

imidazo

trans

diamine

pyridazine

Prior art date

2005-09-22

Links

• Espacenet
• Global Dossier
• Discuss

• 108091000080 Phosphotransferase Proteins 0.000 title abstract description 17
• 102000020233 phosphotransferase Human genes 0.000 title abstract description 17
• 150000002391 heterocyclic compounds Chemical class 0.000 title description 2
• 150000001875 compounds Chemical class 0.000 claims abstract description 179
• 238000000034 method Methods 0.000 claims abstract description 72
• 150000003839 salts Chemical class 0.000 claims abstract description 56
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 34
• 201000010099 disease Diseases 0.000 claims abstract description 27
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
• -1 bicyclo [2.2.2] octyl Chemical group 0.000 claims description 270
• 125000000217 alkyl group Chemical group 0.000 claims description 127
• 239000000203 mixture Substances 0.000 claims description 120
• 229910052739 hydrogen Inorganic materials 0.000 claims description 117
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 84
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 76
• 125000002947 alkylene group Chemical group 0.000 claims description 47
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 42
• 239000001257 hydrogen Substances 0.000 claims description 40
• 125000004433 nitrogen atom Chemical group N* 0.000 claims description 39
• 229910052757 nitrogen Inorganic materials 0.000 claims description 37
• PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims description 36
• 125000003118 aryl group Chemical group 0.000 claims description 35
• 229910052736 halogen Inorganic materials 0.000 claims description 32
• 150000002367 halogens Chemical class 0.000 claims description 32
• 125000004432 carbon atom Chemical group C* 0.000 claims description 31
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 28
• KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 23
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 23
• 150000004985 diamines Chemical class 0.000 claims description 21
• 230000001575 pathological effect Effects 0.000 claims description 19
• 238000011282 treatment Methods 0.000 claims description 19
• 125000005842 heteroatom Chemical group 0.000 claims description 18
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 17
• 125000000623 heterocyclic group Chemical group 0.000 claims description 16
• 125000003386 piperidinyl group Chemical group 0.000 claims description 15
• 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 15
• 150000002431 hydrogen Chemical class 0.000 claims description 14
• ZWBFLQKNWXAVDT-UHFFFAOYSA-N imidazo[1,2-b]pyridazine-6,8-diamine Chemical compound N1=C(N)C=C(N)C2=NC=CN21 ZWBFLQKNWXAVDT-UHFFFAOYSA-N 0.000 claims description 12
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 10
• 125000002541 furyl group Chemical group 0.000 claims description 10
• 201000008482 osteoarthritis Diseases 0.000 claims description 10
• YKEIADGIWRNLHF-UHFFFAOYSA-N 2-(4-ethoxyphenyl)imidazo[1,2-b]pyridazin-8-amine Chemical compound C1=CC(OCC)=CC=C1C1=CN(N=CC=C2N)C2=N1 YKEIADGIWRNLHF-UHFFFAOYSA-N 0.000 claims description 9
• MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 9
• 125000000714 pyrimidinyl group Chemical group 0.000 claims description 9
• 206010063837 Reperfusion injury Diseases 0.000 claims description 8
• 239000003937 drug carrier Substances 0.000 claims description 8
• 125000001188 haloalkyl group Chemical group 0.000 claims description 8
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
• 125000002950 monocyclic group Chemical group 0.000 claims description 8
• 125000002757 morpholinyl group Chemical group 0.000 claims description 8
• KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims description 7
• 206010040070 Septic Shock Diseases 0.000 claims description 7
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 7
• 239000003085 diluting agent Substances 0.000 claims description 7
• 125000005843 halogen group Chemical group 0.000 claims description 7
• 125000002883 imidazolyl group Chemical group 0.000 claims description 7
• 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 6
• RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 6
• 206010009900 Colitis ulcerative Diseases 0.000 claims description 6
• 241000124008 Mammalia Species 0.000 claims description 6
• 208000034578 Multiple myelomas Diseases 0.000 claims description 6
• 206010035226 Plasma cell myeloma Diseases 0.000 claims description 6
• 201000006704 Ulcerative Colitis Diseases 0.000 claims description 6
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 6
• 208000015181 infectious disease Diseases 0.000 claims description 6
• 230000000302 ischemic effect Effects 0.000 claims description 6
• 229910052760 oxygen Inorganic materials 0.000 claims description 6
• 125000004193 piperazinyl group Chemical group 0.000 claims description 6
• 125000003226 pyrazolyl group Chemical group 0.000 claims description 6
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
• 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 5
• 208000002193 Pain Diseases 0.000 claims description 5
• 201000004681 Psoriasis Diseases 0.000 claims description 5
• 230000001684 chronic effect Effects 0.000 claims description 5
• 208000035475 disorder Diseases 0.000 claims description 5
• 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 5
• 230000036407 pain Effects 0.000 claims description 5
• 125000004076 pyridyl group Chemical group 0.000 claims description 5
• 125000000335 thiazolyl group Chemical group 0.000 claims description 5
• 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims description 4
• 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims description 4
• 208000024827 Alzheimer disease Diseases 0.000 claims description 4
• 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 4
• 206010006895 Cachexia Diseases 0.000 claims description 4
• 208000011231 Crohn disease Diseases 0.000 claims description 4
• 201000005569 Gout Diseases 0.000 claims description 4
• 206010028980 Neoplasm Diseases 0.000 claims description 4
• 208000001132 Osteoporosis Diseases 0.000 claims description 4
• 201000011152 Pemphigus Diseases 0.000 claims description 4
• 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 4
• 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 4
• 208000006011 Stroke Diseases 0.000 claims description 4
• 108090000190 Thrombin Proteins 0.000 claims description 4
• 230000002917 arthritic effect Effects 0.000 claims description 4
• 230000015572 biosynthetic process Effects 0.000 claims description 4
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
• 208000027866 inflammatory disease Diseases 0.000 claims description 4
• 208000014674 injury Diseases 0.000 claims description 4
• 230000003211 malignant effect Effects 0.000 claims description 4
• 208000010125 myocardial infarction Diseases 0.000 claims description 4
• 230000004770 neurodegeneration Effects 0.000 claims description 4
• 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
• 201000001976 pemphigus vulgaris Diseases 0.000 claims description 4
• 125000000168 pyrrolyl group Chemical group 0.000 claims description 4
• 125000003831 tetrazolyl group Chemical group 0.000 claims description 4
• 229960004072 thrombin Drugs 0.000 claims description 4
• 125000001425 triazolyl group Chemical group 0.000 claims description 4
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 3
• DVSLBDBGAXXLKZ-UHFFFAOYSA-N 2,3-diethylbenzamide Chemical compound CCC1=CC=CC(C(N)=O)=C1CC DVSLBDBGAXXLKZ-UHFFFAOYSA-N 0.000 claims description 3
• 208000030507 AIDS Diseases 0.000 claims description 3
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 3
• 208000004429 Bacillary Dysentery Diseases 0.000 claims description 3
• 201000006474 Brain Ischemia Diseases 0.000 claims description 3
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 3
• 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 claims description 3
• 208000003807 Graves Disease Diseases 0.000 claims description 3
• 208000015023 Graves' disease Diseases 0.000 claims description 3
• 208000031886 HIV Infections Diseases 0.000 claims description 3
• 208000037357 HIV infectious disease Diseases 0.000 claims description 3
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
• 208000007766 Kaposi sarcoma Diseases 0.000 claims description 3
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 3
• 206010029113 Neovascularisation Diseases 0.000 claims description 3
• 208000018737 Parkinson disease Diseases 0.000 claims description 3
• 206010037660 Pyrexia Diseases 0.000 claims description 3
• 206010040047 Sepsis Diseases 0.000 claims description 3
• 206010040550 Shigella infections Diseases 0.000 claims description 3
• 241000700605 Viruses Species 0.000 claims description 3
• 208000006673 asthma Diseases 0.000 claims description 3
• SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 3
• 208000001763 cytomegalovirus retinitis Diseases 0.000 claims description 3
• 125000005959 diazepanyl group Chemical group 0.000 claims description 3
• 201000011066 hemangioma Diseases 0.000 claims description 3
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 3
• 201000006417 multiple sclerosis Diseases 0.000 claims description 3
• 230000036303 septic shock Effects 0.000 claims description 3
• 201000005113 shigellosis Diseases 0.000 claims description 3
• 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 3
• 230000008736 traumatic injury Effects 0.000 claims description 3
• QOVLJBFQXNGGDV-UHFFFAOYSA-N 1,3-dihydro-1,2,4-triazine-2,4-diamine Chemical compound NN1CN(N)C=CN1 QOVLJBFQXNGGDV-UHFFFAOYSA-N 0.000 claims description 2
• 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims description 2
• 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 claims description 2
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
• 201000001320 Atherosclerosis Diseases 0.000 claims description 2
• 206010055128 Autoimmune neutropenia Diseases 0.000 claims description 2
• 241000713704 Bovine immunodeficiency virus Species 0.000 claims description 2
• ISLYOFBOHHGXPK-MQMHXKEQSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C(C(N)=O)=CN=C2C(NC=2C=CC=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C(C(N)=O)=CN=C2C(NC=2C=CC=CC=2)=C1 ISLYOFBOHHGXPK-MQMHXKEQSA-N 0.000 claims description 2
• MDDIJEDLJOBHEY-CTYIDZIISA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC(=O)NC=2C=CC=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC(=O)NC=2C=CC=CC=2)=C1 MDDIJEDLJOBHEY-CTYIDZIISA-N 0.000 claims description 2
• PCUTWNIUUUWMIF-IRJFHVNHSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(NC(=O)NC=3C=CC=CC=3)=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(NC(=O)NC=3C=CC=CC=3)=CC=2)=C1 PCUTWNIUUUWMIF-IRJFHVNHSA-N 0.000 claims description 2
• GAMHGYMOZVTGIY-HDJSIYSDSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NS(=O)(=O)C=2C=CC=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NS(=O)(=O)C=2C=CC=CC=2)=C1 GAMHGYMOZVTGIY-HDJSIYSDSA-N 0.000 claims description 2
• LOYSCGPAOMSQLY-SAZUREKKSA-N C1C[C@@H](N)CC[C@@H]1OC1=NN2C(C#N)=CN=C2C(NC=2C=CC=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1OC1=NN2C(C#N)=CN=C2C(NC=2C=CC=CC=2)=C1 LOYSCGPAOMSQLY-SAZUREKKSA-N 0.000 claims description 2
• 206010058019 Cancer Pain Diseases 0.000 claims description 2
• 206010007572 Cardiac hypertrophy Diseases 0.000 claims description 2
• 208000006029 Cardiomegaly Diseases 0.000 claims description 2
• 206010008120 Cerebral ischaemia Diseases 0.000 claims description 2
• 206010063094 Cerebral malaria Diseases 0.000 claims description 2
• 206010008909 Chronic Hepatitis Diseases 0.000 claims description 2
• 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
• 208000037487 Endotoxemia Diseases 0.000 claims description 2
• 241000713800 Feline immunodeficiency virus Species 0.000 claims description 2
• 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
• 206010018634 Gouty Arthritis Diseases 0.000 claims description 2
• 206010019233 Headaches Diseases 0.000 claims description 2
• 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 2
• 208000005176 Hepatitis C Diseases 0.000 claims description 2
• 206010019755 Hepatitis chronic active Diseases 0.000 claims description 2
• 206010020751 Hypersensitivity Diseases 0.000 claims description 2
• XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 2
• 206010061598 Immunodeficiency Diseases 0.000 claims description 2
• 208000029462 Immunodeficiency disease Diseases 0.000 claims description 2
• 206010061218 Inflammation Diseases 0.000 claims description 2
• 206010028289 Muscle atrophy Diseases 0.000 claims description 2
• 208000000112 Myalgia Diseases 0.000 claims description 2
• FFUQTVMHEOZHDE-HDJSIYSDSA-N N=1N2C=CN=C2C(NC=2C=C(O)C=CC=2)=C(C)C=1N[C@H]1CC[C@H](N)CC1 Chemical compound N=1N2C=CN=C2C(NC=2C=C(O)C=CC=2)=C(C)C=1N[C@H]1CC[C@H](N)CC1 FFUQTVMHEOZHDE-HDJSIYSDSA-N 0.000 claims description 2
• 206010030113 Oedema Diseases 0.000 claims description 2
• 206010033645 Pancreatitis Diseases 0.000 claims description 2
• 208000033464 Reiter syndrome Diseases 0.000 claims description 2
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 2
• 206010039710 Scleroderma Diseases 0.000 claims description 2
• 201000010001 Silicosis Diseases 0.000 claims description 2
• 208000007536 Thrombosis Diseases 0.000 claims description 2
• 206010044248 Toxic shock syndrome Diseases 0.000 claims description 2
• 231100000650 Toxic shock syndrome Toxicity 0.000 claims description 2
• 206010048873 Traumatic arthritis Diseases 0.000 claims description 2
• 230000001154 acute effect Effects 0.000 claims description 2
• 231100000354 acute hepatitis Toxicity 0.000 claims description 2
• 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 2
• 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 2
• 230000007815 allergy Effects 0.000 claims description 2
• 230000036592 analgesia Effects 0.000 claims description 2
• 230000002491 angiogenic effect Effects 0.000 claims description 2
• 206010003246 arthritis Diseases 0.000 claims description 2
• 201000008937 atopic dermatitis Diseases 0.000 claims description 2
• 201000005000 autoimmune gastritis Diseases 0.000 claims description 2
• 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 2
• 229940092714 benzenesulfonic acid Drugs 0.000 claims description 2
• 230000000747 cardiac effect Effects 0.000 claims description 2
• 230000002490 cerebral effect Effects 0.000 claims description 2
• 206010008118 cerebral infarction Diseases 0.000 claims description 2
• 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
• 206010012601 diabetes mellitus Diseases 0.000 claims description 2
• 201000006549 dyspepsia Diseases 0.000 claims description 2
• 239000002158 endotoxin Substances 0.000 claims description 2
• 229910052731 fluorine Inorganic materials 0.000 claims description 2
• 239000011737 fluorine Substances 0.000 claims description 2
• 231100000869 headache Toxicity 0.000 claims description 2
• 208000024798 heartburn Diseases 0.000 claims description 2
• 208000006454 hepatitis Diseases 0.000 claims description 2
• 208000005252 hepatitis A Diseases 0.000 claims description 2
• 208000002672 hepatitis B Diseases 0.000 claims description 2
• 206010020718 hyperplasia Diseases 0.000 claims description 2
• YLXWTAXPOOYRSL-UHFFFAOYSA-N imidazo[1,2-b]pyridazine-3-carbonitrile Chemical compound C1=CC=NN2C(C#N)=CN=C21 YLXWTAXPOOYRSL-UHFFFAOYSA-N 0.000 claims description 2
• 230000007813 immunodeficiency Effects 0.000 claims description 2
• 230000008595 infiltration Effects 0.000 claims description 2
• 238000001764 infiltration Methods 0.000 claims description 2
• 230000004054 inflammatory process Effects 0.000 claims description 2
• 206010022000 influenza Diseases 0.000 claims description 2
• 208000028867 ischemia Diseases 0.000 claims description 2
• 210000003734 kidney Anatomy 0.000 claims description 2
• GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims description 2
• 206010028417 myasthenia gravis Diseases 0.000 claims description 2
• 208000031225 myocardial ischemia Diseases 0.000 claims description 2
• 230000002232 neuromuscular Effects 0.000 claims description 2
• 230000003448 neutrophilic effect Effects 0.000 claims description 2
• 210000000056 organ Anatomy 0.000 claims description 2
• WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 claims description 2
• 208000002574 reactive arthritis Diseases 0.000 claims description 2
• 201000005404 rubella Diseases 0.000 claims description 2
• 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 2
• 125000003107 substituted aryl group Chemical group 0.000 claims description 2
• 201000004595 synovitis Diseases 0.000 claims description 2
• 206010043554 thrombocytopenia Diseases 0.000 claims description 2
• 208000004371 toothache Diseases 0.000 claims description 2
• 201000008827 tuberculosis Diseases 0.000 claims description 2
• 230000002792 vascular Effects 0.000 claims description 2
• LFEXGBPVZBXATF-UHFFFAOYSA-N 2,3-dimethylbenzenesulfonamide Chemical compound CC1=CC=CC(S(N)(=O)=O)=C1C LFEXGBPVZBXATF-UHFFFAOYSA-N 0.000 claims 4
• MWEVZGDZQRMVPI-VHPWLNBFSA-N N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC=CC2=CC=CC=C12)N Chemical compound N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC=CC2=CC=CC=C12)N MWEVZGDZQRMVPI-VHPWLNBFSA-N 0.000 claims 2
• HIFBSFZYMIEPJS-UHFFFAOYSA-N 2,3-diethylbenzenesulfonamide Chemical compound CCC1=CC=CC(S(N)(=O)=O)=C1CC HIFBSFZYMIEPJS-UHFFFAOYSA-N 0.000 claims 1
• CZYTUNVGDISHLR-UHFFFAOYSA-N 2-[1-[8-(4-ethoxyanilino)imidazo[1,2-b]pyridazin-6-yl]piperidin-4-yl]ethanol Chemical compound C1=CC(OCC)=CC=C1NC1=CC(N2CCC(CCO)CC2)=NN2C1=NC=C2 CZYTUNVGDISHLR-UHFFFAOYSA-N 0.000 claims 1
• SBXDENYROQKXBE-UHFFFAOYSA-N 2-phenylbenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=CC=C1 SBXDENYROQKXBE-UHFFFAOYSA-N 0.000 claims 1
• FKCPMMPQQLCZOL-UHFFFAOYSA-N 2-phenylimidazo[1,2-b]pyridazine-6,8-diamine Chemical compound C=1N2N=C(N)C=C(N)C2=NC=1C1=CC=CC=C1 FKCPMMPQQLCZOL-UHFFFAOYSA-N 0.000 claims 1
• 201000011244 Acrocallosal syndrome Diseases 0.000 claims 1
• 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
• 208000006386 Bone Resorption Diseases 0.000 claims 1
• QLRLSENDSYMXLR-SKIQCWHVSA-N C(C)N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC=CC=C1)N Chemical compound C(C)N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC=CC=C1)N QLRLSENDSYMXLR-SKIQCWHVSA-N 0.000 claims 1
• UGFKCXAJYGGZGQ-CZIWCDLHSA-N C1=CC(NC(=O)C)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound C1=CC(NC(=O)C)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 UGFKCXAJYGGZGQ-CZIWCDLHSA-N 0.000 claims 1
• GCLLKMQUUBAPQB-CTYIDZIISA-N C1=CC(NS(=O)(=O)C)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 GCLLKMQUUBAPQB-CTYIDZIISA-N 0.000 claims 1
• PDEFJRDSURAZNG-KOMQPUFPSA-N C1=CC(OCC)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2C#N Chemical compound C1=CC(OCC)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2C#N PDEFJRDSURAZNG-KOMQPUFPSA-N 0.000 claims 1
• HBJLBRUEPVJVMT-KOMQPUFPSA-N C1=CC(S(=O)(=O)N(C)C)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound C1=CC(S(=O)(=O)N(C)C)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 HBJLBRUEPVJVMT-KOMQPUFPSA-N 0.000 claims 1
• HBJLBRUEPVJVMT-FZNQNYSPSA-N C1=CC(S(=O)(=O)N(C)C)=CC=C1NC1=CC(N[C@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound C1=CC(S(=O)(=O)N(C)C)=CC=C1NC1=CC(N[C@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 HBJLBRUEPVJVMT-FZNQNYSPSA-N 0.000 claims 1
• VJIPYULVLXMZOC-CTYIDZIISA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C(C#N)=CN=C2C(NC=2C=CC=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C(C#N)=CN=C2C(NC=2C=CC=CC=2)=C1 VJIPYULVLXMZOC-CTYIDZIISA-N 0.000 claims 1
• IEOYOODRCOAEMG-SHTZXODSSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC(=O)C=2C=CC=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC(=O)C=2C=CC=CC=2)=C1 IEOYOODRCOAEMG-SHTZXODSSA-N 0.000 claims 1
• ZSFRWNNKBMIOOC-JOCQHMNTSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C(=CC=CC=2)O)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C(=CC=CC=2)O)=C1 ZSFRWNNKBMIOOC-JOCQHMNTSA-N 0.000 claims 1
• ADXLFHFPANLMRH-SHTZXODSSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C(C=CC=2)C#N)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C(C=CC=2)C#N)=C1 ADXLFHFPANLMRH-SHTZXODSSA-N 0.000 claims 1
• INILGZLACGMTIF-HDJSIYSDSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C(C=CC=2)C(O)=O)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C(C=CC=2)C(O)=O)=C1 INILGZLACGMTIF-HDJSIYSDSA-N 0.000 claims 1
• BIUNZHGGBJCAFD-JOCQHMNTSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C(O)C=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C(O)C=CC=2)=C1 BIUNZHGGBJCAFD-JOCQHMNTSA-N 0.000 claims 1
• FVKAFOLBMYXPDE-KOMQPUFPSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C#N)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C#N)=C1 FVKAFOLBMYXPDE-KOMQPUFPSA-N 0.000 claims 1
• BFRUMZZTBHOIAP-CTYIDZIISA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C(O)=O)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C(O)=O)=C1 BFRUMZZTBHOIAP-CTYIDZIISA-N 0.000 claims 1
• MPBKGMFEWBLBKS-KESTWPANSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(NC(=O)C=3C=CC=CC=3)=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(NC(=O)C=3C=CC=CC=3)=CC=2)=C1 MPBKGMFEWBLBKS-KESTWPANSA-N 0.000 claims 1
• QUQLQIANWFAGOL-MQMHXKEQSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(O)=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(O)=CC=2)=C1 QUQLQIANWFAGOL-MQMHXKEQSA-N 0.000 claims 1
• UIKAFEQGIGFHAO-UHFFFAOYSA-N CCOC1=CC=C(C=C1)C2=CN3C(=N2)C(=CC(=N3)N4CCNCC4)N Chemical compound CCOC1=CC=C(C=C1)C2=CN3C(=N2)C(=CC(=N3)N4CCNCC4)N UIKAFEQGIGFHAO-UHFFFAOYSA-N 0.000 claims 1
• DFCMSUYLMZXEDW-VNHLFDKOSA-N CN[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC=CC=C1)N Chemical compound CN[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC=CC=C1)N DFCMSUYLMZXEDW-VNHLFDKOSA-N 0.000 claims 1
• 241000283073 Equus caballus Species 0.000 claims 1
• CJUABQXTORYFJG-JCNLHEQBSA-N N=1N2C(C#N)=CN=C2C(NC=2C=CC=CC=2)=C(C(C)C)C=1N[C@H]1CC[C@H](N)CC1 Chemical compound N=1N2C(C#N)=CN=C2C(NC=2C=CC=CC=2)=C(C(C)C)C=1N[C@H]1CC[C@H](N)CC1 CJUABQXTORYFJG-JCNLHEQBSA-N 0.000 claims 1
• JYEQQYUSNBKXRA-KOMQPUFPSA-N N=1N2C=CN=C2C(NC=2C=CC(=CC=2)C(O)=O)=C(C)C=1N[C@H]1CC[C@H](N)CC1 Chemical compound N=1N2C=CN=C2C(NC=2C=CC(=CC=2)C(O)=O)=C(C)C=1N[C@H]1CC[C@H](N)CC1 JYEQQYUSNBKXRA-KOMQPUFPSA-N 0.000 claims 1
• XXJDONDSTFIQFR-RVWIWJKTSA-N N=1N2C=CN=C2C(NC=2C=CC(NC(=O)NC=3C=CC=CC=3)=CC=2)=C(C)C=1N[C@@H]1CC[C@H](N)CC1 Chemical compound N=1N2C=CN=C2C(NC=2C=CC(NC(=O)NC=3C=CC=CC=3)=CC=2)=C(C)C=1N[C@@H]1CC[C@H](N)CC1 XXJDONDSTFIQFR-RVWIWJKTSA-N 0.000 claims 1
• XXJDONDSTFIQFR-XGAFWQRZSA-N N=1N2C=CN=C2C(NC=2C=CC(NC(=O)NC=3C=CC=CC=3)=CC=2)=C(C)C=1N[C@H]1CC[C@H](N)CC1 Chemical compound N=1N2C=CN=C2C(NC=2C=CC(NC(=O)NC=3C=CC=CC=3)=CC=2)=C(C)C=1N[C@H]1CC[C@H](N)CC1 XXJDONDSTFIQFR-XGAFWQRZSA-N 0.000 claims 1
• OTGBKQRZQSOPSC-NMUBWLRRSA-N N[C@@H]1CC[C@H](CC1)C1(C(=C(C=2N(N1)C=CN=2)NC1=CC=C(C=C1)OCC)C1=CC=CC=C1)N Chemical compound N[C@@H]1CC[C@H](CC1)C1(C(=C(C=2N(N1)C=CN=2)NC1=CC=C(C=C1)OCC)C1=CC=CC=C1)N OTGBKQRZQSOPSC-NMUBWLRRSA-N 0.000 claims 1
• LKDADLNTHXOWJS-MEQCVUQCSA-N N[C@@H]1CC[C@H](CC1)C1(C(=C(C=2N(N1)C=CN=2)NC1=CC=CC=C1)C1=CC=CC=C1)N Chemical compound N[C@@H]1CC[C@H](CC1)C1(C(=C(C=2N(N1)C=CN=2)NC1=CC=CC=C1)C1=CC=CC=C1)N LKDADLNTHXOWJS-MEQCVUQCSA-N 0.000 claims 1
• GHYNOJCJPCZNFN-FDTIFPJHSA-N N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=C(C=C(C=C1)C)F)N Chemical compound N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=C(C=C(C=C1)C)F)N GHYNOJCJPCZNFN-FDTIFPJHSA-N 0.000 claims 1
• HGCCZCWMFFJMPA-YVTDUHFPSA-N N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=C(C=C(C=C1)Cl)F)N Chemical compound N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=C(C=C(C=C1)Cl)F)N HGCCZCWMFFJMPA-YVTDUHFPSA-N 0.000 claims 1
• CADUNQFDLPZGQY-FDTIFPJHSA-N N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=C(C=CC(=C1)C)F)N Chemical compound N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=C(C=CC(=C1)C)F)N CADUNQFDLPZGQY-FDTIFPJHSA-N 0.000 claims 1
• IXQQZDHUOUSZAL-SKIQCWHVSA-N N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=C(C=CC=C1)CC)N Chemical compound N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=C(C=CC=C1)CC)N IXQQZDHUOUSZAL-SKIQCWHVSA-N 0.000 claims 1
• PWQZARQTEOKDHG-IILDZGFYSA-N N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=C(C=CC=C1)Cl)N Chemical compound N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=C(C=CC=C1)Cl)N PWQZARQTEOKDHG-IILDZGFYSA-N 0.000 claims 1
• VBFWBZFTJYYXJZ-NUJJYFHVSA-N N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=C(C=CC=C1)OC1=CC=CC=C1)N Chemical compound N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=C(C=CC=C1)OC1=CC=CC=C1)N VBFWBZFTJYYXJZ-NUJJYFHVSA-N 0.000 claims 1
• AEGMGILIWDBIFV-FDTIFPJHSA-N N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC(=C(C=C1)C)F)N Chemical compound N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC(=C(C=C1)C)F)N AEGMGILIWDBIFV-FDTIFPJHSA-N 0.000 claims 1
• FLLQCHGZLWBCTB-FDTIFPJHSA-N N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC(=C(C=C1)Cl)C)N Chemical compound N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC(=C(C=C1)Cl)C)N FLLQCHGZLWBCTB-FDTIFPJHSA-N 0.000 claims 1
• XASDFAJYQZKBBH-FDTIFPJHSA-N N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC(=C(C=C1)F)C)N Chemical compound N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC(=C(C=C1)F)C)N XASDFAJYQZKBBH-FDTIFPJHSA-N 0.000 claims 1
• BGKQTOVKPOPFPK-ZZABYMOQSA-N N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC(=CC(=C1)Cl)Cl)N Chemical compound N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC(=CC(=C1)Cl)Cl)N BGKQTOVKPOPFPK-ZZABYMOQSA-N 0.000 claims 1
• SAPNJWXKGFDGFN-OEVKCDGTSA-N N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC(=CC(=C1)OC)OC)N Chemical compound N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC(=CC(=C1)OC)OC)N SAPNJWXKGFDGFN-OEVKCDGTSA-N 0.000 claims 1
• QOYMUHJYYXLGJU-UYJZDEDHSA-N N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC(=CC=C1)C(C)C)N Chemical compound N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC(=CC=C1)C(C)C)N QOYMUHJYYXLGJU-UYJZDEDHSA-N 0.000 claims 1
• ROVKYFLWBFLGDC-FWNFJVJXSA-N N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC(=CC=C1)C(F)(F)F)N Chemical compound N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC(=CC=C1)C(F)(F)F)N ROVKYFLWBFLGDC-FWNFJVJXSA-N 0.000 claims 1
• XUDOYLCTEBBJCW-SKIQCWHVSA-N N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC(=CC=C1)CC)N Chemical compound N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC(=CC=C1)CC)N XUDOYLCTEBBJCW-SKIQCWHVSA-N 0.000 claims 1
• GWNMWOABOPWFGV-FPCUACJBSA-N N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC(=CC=C1)CC1=CC=CC=C1)N Chemical compound N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC(=CC=C1)CC1=CC=CC=C1)N GWNMWOABOPWFGV-FPCUACJBSA-N 0.000 claims 1
• RRWGQLGTGDOZNU-FWNFJVJXSA-N N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC(=CC=C1)Cl)N Chemical compound N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC(=CC=C1)Cl)N RRWGQLGTGDOZNU-FWNFJVJXSA-N 0.000 claims 1
• XFSLQFZUSQTRFJ-CZEDARRBSA-N N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC(=CC=C1)OC(C)C)N Chemical compound N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC(=CC=C1)OC(C)C)N XFSLQFZUSQTRFJ-CZEDARRBSA-N 0.000 claims 1
• RKJCWONUBSBCES-IILDZGFYSA-N N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC(=CC=C1)OC(F)(F)F)N Chemical compound N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC(=CC=C1)OC(F)(F)F)N RKJCWONUBSBCES-IILDZGFYSA-N 0.000 claims 1
• PPUIYKZQZHFHSR-NUJJYFHVSA-N N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC(=CC=C1)OC1=CC=CC=C1)N Chemical compound N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC(=CC=C1)OC1=CC=CC=C1)N PPUIYKZQZHFHSR-NUJJYFHVSA-N 0.000 claims 1
• OJNGVJLBWLDVSI-FDTIFPJHSA-N N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC(=CC=C1)SC)N Chemical compound N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC(=CC=C1)SC)N OJNGVJLBWLDVSI-FDTIFPJHSA-N 0.000 claims 1
• UFBXEHDGKIINGJ-CVBNSBKJSA-N N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC(=NC=C1)C)N Chemical compound N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC(=NC=C1)C)N UFBXEHDGKIINGJ-CVBNSBKJSA-N 0.000 claims 1
• CMIXQGQRGPIXDF-VTBPVJSFSA-N N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC=C(C2=CC=CC=C12)Cl)N Chemical compound N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC=C(C2=CC=CC=C12)Cl)N CMIXQGQRGPIXDF-VTBPVJSFSA-N 0.000 claims 1
• IFFDLHHGGMPJEX-BVWRGAJNSA-N N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC=C(C=C1)C(=O)N1CC(CC1)C1=CC=CC=C1)N Chemical compound N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC=C(C=C1)C(=O)N1CC(CC1)C1=CC=CC=C1)N IFFDLHHGGMPJEX-BVWRGAJNSA-N 0.000 claims 1
• TZAYVAYGPISLSC-NCHKGXLSSA-N N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC=C(C=C1)C(=O)N1CCCC1)N Chemical compound N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC=C(C=C1)C(=O)N1CCCC1)N TZAYVAYGPISLSC-NCHKGXLSSA-N 0.000 claims 1
• JGSAUJSOCHLKMD-MEQCVUQCSA-N N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC=C(C=C1)C(=O)N1CCCCC1)N Chemical compound N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC=C(C=C1)C(=O)N1CCCCC1)N JGSAUJSOCHLKMD-MEQCVUQCSA-N 0.000 claims 1
• IYBZEEBLGJSTOI-VHPWLNBFSA-N N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC=C(C=C1)C(C)(C)C)N Chemical compound N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC=C(C=C1)C(C)(C)C)N IYBZEEBLGJSTOI-VHPWLNBFSA-N 0.000 claims 1
• FVVBBLLTLVOSOH-UYJZDEDHSA-N N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC=C(C=C1)C(C)C)N Chemical compound N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC=C(C=C1)C(C)C)N FVVBBLLTLVOSOH-UYJZDEDHSA-N 0.000 claims 1
• LWEGLTKNADYLOW-YYSPQECZSA-N N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC=C(C=C1)C1=C(C=CC=C1)C)N Chemical compound N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC=C(C=C1)C1=C(C=CC=C1)C)N LWEGLTKNADYLOW-YYSPQECZSA-N 0.000 claims 1
• NJUISEBKWYXJQW-QJNLCEDISA-N N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC=C(C=C1)C1=CC(=CC=C1)Cl)N Chemical compound N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC=C(C=C1)C1=CC(=CC=C1)Cl)N NJUISEBKWYXJQW-QJNLCEDISA-N 0.000 claims 1
• VYHRGZXVHVRPBY-FPCUACJBSA-N N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC=C(C=C1)C1=CC=C(C=C1)C)N Chemical compound N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC=C(C=C1)C1=CC=C(C=C1)C)N VYHRGZXVHVRPBY-FPCUACJBSA-N 0.000 claims 1
• OLIBNIGVBXCLLA-QJNLCEDISA-N N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC=C(C=C1)C1=CC=C(C=C1)Cl)N Chemical compound N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC=C(C=C1)C1=CC=C(C=C1)Cl)N OLIBNIGVBXCLLA-QJNLCEDISA-N 0.000 claims 1
• NGBYPEWTMGLOBH-FDTIFPJHSA-N N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC=C(C=C1)C1=NN=NN1)N Chemical compound N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC=C(C=C1)C1=NN=NN1)N NGBYPEWTMGLOBH-FDTIFPJHSA-N 0.000 claims 1
• WTEFSENXCICSHK-OPYUEGPBSA-N N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC=C(C=C1)C1CCCCC1)N Chemical compound N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC=C(C=C1)C1CCCCC1)N WTEFSENXCICSHK-OPYUEGPBSA-N 0.000 claims 1
• PHMSNUGINNALNS-SKIQCWHVSA-N N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC=C(C=C1)CC)N Chemical compound N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC=C(C=C1)CC)N PHMSNUGINNALNS-SKIQCWHVSA-N 0.000 claims 1
• VNVCBOPGANJFJK-FPCUACJBSA-N N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC=C(C=C1)CC1=CC=CC=C1)N Chemical compound N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC=C(C=C1)CC1=CC=CC=C1)N VNVCBOPGANJFJK-FPCUACJBSA-N 0.000 claims 1
• NWNIBHFWISQWIG-UYJZDEDHSA-N N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC=C(C=C1)CCC)N Chemical compound N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC=C(C=C1)CCC)N NWNIBHFWISQWIG-UYJZDEDHSA-N 0.000 claims 1
• RKNWKZFOZRGREJ-IQHDZCMKSA-N N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC=C(C=C1)CCCC)N Chemical compound N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC=C(C=C1)CCCC)N RKNWKZFOZRGREJ-IQHDZCMKSA-N 0.000 claims 1
• RVGKCIVZVIPKJV-FWNFJVJXSA-N N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC=C(C=C1)Cl)N Chemical compound N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC=C(C=C1)Cl)N RVGKCIVZVIPKJV-FWNFJVJXSA-N 0.000 claims 1
• OMLLNRBWHOWEIO-VHPWLNBFSA-N N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC=C(C=C1)N1CCOCC1)N Chemical compound N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC=C(C=C1)N1CCOCC1)N OMLLNRBWHOWEIO-VHPWLNBFSA-N 0.000 claims 1
• BVQURZUKPUUNIK-CZEDARRBSA-N N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC=C(C=C1)OC(C)C)N Chemical compound N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC=C(C=C1)OC(C)C)N BVQURZUKPUUNIK-CZEDARRBSA-N 0.000 claims 1
• IBVZGUHXUCAFGO-VHPWLNBFSA-N N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC=CC=2CCCCC1=2)N Chemical compound N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC=CC=2CCCCC1=2)N IBVZGUHXUCAFGO-VHPWLNBFSA-N 0.000 claims 1
• VUIRXWAMPNAQJX-CIQKOQMRSA-N N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=NC=C(C=C1)C1=CC=CC=C1)N Chemical compound N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=NC=C(C=C1)C1=CC=CC=C1)N VUIRXWAMPNAQJX-CIQKOQMRSA-N 0.000 claims 1
• KODPCHJILWJAJK-QJNLCEDISA-N N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC=1C=C(C=CC=1)C1=CC(=CC=C1)Cl)N Chemical compound N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC=1C=C(C=CC=1)C1=CC(=CC=C1)Cl)N KODPCHJILWJAJK-QJNLCEDISA-N 0.000 claims 1
• DYNQEKAQVZFJGV-OPYUEGPBSA-N N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC=1C=C(C=CC=1)C1=CC=CC=C1)N Chemical compound N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC=1C=C(C=CC=1)C1=CC=CC=C1)N DYNQEKAQVZFJGV-OPYUEGPBSA-N 0.000 claims 1
• SAVFNWGBRBONEL-CZEDARRBSA-N N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC=1C=NC2=CC=CC=C2C=1)N Chemical compound N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC=1C=NC2=CC=CC=C2C=1)N SAVFNWGBRBONEL-CZEDARRBSA-N 0.000 claims 1
• ZCSGJAIKSQWCTI-NYTJIUQPSA-N N[C@H]1CC[C@H](CC1)C1(C(=C(C=2N(N1)C=CN=2)NC1=C(C=CC=C1)C)C)N Chemical compound N[C@H]1CC[C@H](CC1)C1(C(=C(C=2N(N1)C=CN=2)NC1=C(C=CC=C1)C)C)N ZCSGJAIKSQWCTI-NYTJIUQPSA-N 0.000 claims 1
• KTCGSOHAQRQYQG-FSWDVZBNSA-N N[C@H]1CC[C@H](CC1)C1(C(=C(C=2N(N1)C=CN=2)NC1=C(C=CC=C1)F)C)N Chemical compound N[C@H]1CC[C@H](CC1)C1(C(=C(C=2N(N1)C=CN=2)NC1=C(C=CC=C1)F)C)N KTCGSOHAQRQYQG-FSWDVZBNSA-N 0.000 claims 1
• LHHNVACGOMAYAU-NYTJIUQPSA-N N[C@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC(=C(C=C1)C)C)N Chemical compound N[C@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC(=C(C=C1)C)C)N LHHNVACGOMAYAU-NYTJIUQPSA-N 0.000 claims 1
• HWCIBUNZNBVAIM-NHJWOMDBSA-N N[C@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC=C(C=C1)C(=O)N1CCOCC1)N Chemical compound N[C@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC=C(C=C1)C(=O)N1CCOCC1)N HWCIBUNZNBVAIM-NHJWOMDBSA-N 0.000 claims 1
• UFJPJJXAHOSMCF-RTHVDDQRSA-N N[C@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC=C(C=C1)C)N Chemical compound N[C@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=CC=C(C=C1)C)N UFJPJJXAHOSMCF-RTHVDDQRSA-N 0.000 claims 1
• RQLNPAQKYIPXMQ-RTHVDDQRSA-N N[C@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=NC(=CC(=C1)C)C)N Chemical compound N[C@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=NC(=CC(=C1)C)C)N RQLNPAQKYIPXMQ-RTHVDDQRSA-N 0.000 claims 1
• VUIRXWAMPNAQJX-LIMIJEPZSA-N N[C@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=NC=C(C=C1)C1=CC=CC=C1)N Chemical compound N[C@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)NC1=NC=C(C=C1)C1=CC=CC=C1)N VUIRXWAMPNAQJX-LIMIJEPZSA-N 0.000 claims 1
• 241000009328 Perro Species 0.000 claims 1
• 206010043781 Thyroiditis chronic Diseases 0.000 claims 1
• 208000019905 acrocephalosyndactyly Diseases 0.000 claims 1
• 206010051895 acute chest syndrome Diseases 0.000 claims 1
• 208000007502 anemia Diseases 0.000 claims 1
• 230000024279 bone resorption Effects 0.000 claims 1
• 201000001441 melanoma Diseases 0.000 claims 1
• IMNDHOCGZLYMRO-UHFFFAOYSA-N n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC=C1 IMNDHOCGZLYMRO-UHFFFAOYSA-N 0.000 claims 1
• 201000003651 pulmonary sarcoidosis Diseases 0.000 claims 1
• 231100000241 scar Toxicity 0.000 claims 1
• 230000009772 tissue formation Effects 0.000 claims 1
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract description 8
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 384
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 117
• 239000002904 solvent Substances 0.000 description 114
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 90
• 239000000243 solution Substances 0.000 description 76
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 67
• 239000011541 reaction mixture Substances 0.000 description 61
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 56
• 238000006243 chemical reaction Methods 0.000 description 52
• 229910001868 water Inorganic materials 0.000 description 51
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 40
• 230000014759 maintenance of location Effects 0.000 description 40
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 38
• 239000007787 solid Substances 0.000 description 36
• 125000001424 substituent group Chemical group 0.000 description 36
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 33
• 239000012044 organic layer Substances 0.000 description 33
• 125000001072 heteroaryl group Chemical group 0.000 description 27
• 125000000547 substituted alkyl group Chemical group 0.000 description 27
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 24
• 238000003756 stirring Methods 0.000 description 24
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
• IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 22
• 238000002953 preparative HPLC Methods 0.000 description 22
• VKIRRGRTJUUZHS-UHFFFAOYSA-N cyclohexane-1,4-diamine Chemical compound NC1CCC(N)CC1 VKIRRGRTJUUZHS-UHFFFAOYSA-N 0.000 description 19
• 239000000047 product Substances 0.000 description 19
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
• 239000007858 starting material Substances 0.000 description 17
• 238000004128 high performance liquid chromatography Methods 0.000 description 16
• 239000000155 melt Substances 0.000 description 16
• 125000000304 alkynyl group Chemical group 0.000 description 15
• 230000000694 effects Effects 0.000 description 15
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
• 150000001412 amines Chemical group 0.000 description 14
• 125000004474 heteroalkylene group Chemical group 0.000 description 14
• 239000002244 precipitate Substances 0.000 description 14
• 125000003342 alkenyl group Chemical group 0.000 description 13
• 229910052799 carbon Inorganic materials 0.000 description 13
• 238000001816 cooling Methods 0.000 description 13
• 108090000623 proteins and genes Proteins 0.000 description 13
• 229920006395 saturated elastomer Polymers 0.000 description 13
• 238000006467 substitution reaction Methods 0.000 description 13
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
• 150000004942 imidazo[1,2-b]pyridazines Chemical class 0.000 description 12
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
• 125000003545 alkoxy group Chemical group 0.000 description 11
• 239000012267 brine Substances 0.000 description 11
• 239000010410 layer Substances 0.000 description 11
• 102000004169 proteins and genes Human genes 0.000 description 11
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 11
• 239000000725 suspension Substances 0.000 description 11
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
• 239000002585 base Substances 0.000 description 10
• 239000003814 drug Substances 0.000 description 10
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 10
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 10
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 9
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 9
• 102000004127 Cytokines Human genes 0.000 description 9
• 108090000695 Cytokines Proteins 0.000 description 9
• 102000004190 Enzymes Human genes 0.000 description 9
• 108090000790 Enzymes Proteins 0.000 description 9
• 125000004103 aminoalkyl group Chemical group 0.000 description 9
• 150000001721 carbon Chemical group 0.000 description 9
• 239000012043 crude product Substances 0.000 description 9
• 229940088598 enzyme Drugs 0.000 description 9
• 238000001914 filtration Methods 0.000 description 9
• 238000002360 preparation method Methods 0.000 description 9
• 238000000746 purification Methods 0.000 description 9
• 150000004892 pyridazines Chemical class 0.000 description 9
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
• 239000007864 aqueous solution Substances 0.000 description 8
• 125000002619 bicyclic group Chemical group 0.000 description 8
• 239000000872 buffer Substances 0.000 description 8
• 239000003795 chemical substances by application Substances 0.000 description 8
• 239000000706 filtrate Substances 0.000 description 8
• 230000005855 radiation Effects 0.000 description 8
• 125000005017 substituted alkenyl group Chemical group 0.000 description 8
• LZEJQXOCRMRVNP-UHFFFAOYSA-N 8-bromo-6-chloroimidazo[1,2-b]pyridazine Chemical compound N1=C(Cl)C=C(Br)C2=NC=CN21 LZEJQXOCRMRVNP-UHFFFAOYSA-N 0.000 description 7
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 7
• 125000004450 alkenylene group Chemical group 0.000 description 7
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 7
• 150000002430 hydrocarbons Chemical group 0.000 description 7
• UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 7
• 230000005764 inhibitory process Effects 0.000 description 7
• 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 7
• YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 7
• 239000000741 silica gel Substances 0.000 description 7
• 229910002027 silica gel Inorganic materials 0.000 description 7
• 235000017557 sodium bicarbonate Nutrition 0.000 description 7
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
• 239000000758 substrate Substances 0.000 description 7
• 238000012360 testing method Methods 0.000 description 7
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 7
• 238000003828 vacuum filtration Methods 0.000 description 7
• 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 6
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
• 125000004429 atom Chemical group 0.000 description 6
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
• JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 6
• FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 6
• 229910000024 caesium carbonate Inorganic materials 0.000 description 6
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
• 239000003153 chemical reaction reagent Substances 0.000 description 6
• 238000000605 extraction Methods 0.000 description 6
• 125000004356 hydroxy functional group Chemical group O* 0.000 description 6
• 150000003949 imides Chemical class 0.000 description 6
• 239000007788 liquid Substances 0.000 description 6
• KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 6
• 238000004519 manufacturing process Methods 0.000 description 6
• 239000002609 medium Substances 0.000 description 6
• 239000012038 nucleophile Substances 0.000 description 6
• 239000000546 pharmaceutical excipient Substances 0.000 description 6
• 229940002612 prodrug Drugs 0.000 description 6
• 239000000651 prodrug Substances 0.000 description 6
• 150000003254 radicals Chemical class 0.000 description 6
• 238000004007 reversed phase HPLC Methods 0.000 description 6
• 125000004434 sulfur atom Chemical group 0.000 description 6
• DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 6
• QSKPIOLLBIHNAC-UHFFFAOYSA-N 2-chloro-acetaldehyde Chemical compound ClCC=O QSKPIOLLBIHNAC-UHFFFAOYSA-N 0.000 description 5
• IMPPGHMHELILKG-UHFFFAOYSA-N 4-ethoxyaniline Chemical compound CCOC1=CC=C(N)C=C1 IMPPGHMHELILKG-UHFFFAOYSA-N 0.000 description 5
• 241000699670 Mus sp. Species 0.000 description 5
• AUELWJRRASQDKI-UHFFFAOYSA-N cyclohexyl carbamate Chemical compound NC(=O)OC1CCCCC1 AUELWJRRASQDKI-UHFFFAOYSA-N 0.000 description 5
• 230000002950 deficient Effects 0.000 description 5
• 150000002148 esters Chemical class 0.000 description 5
• 239000005457 ice water Substances 0.000 description 5
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
• LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 5
• 125000004001 thioalkyl group Chemical group 0.000 description 5
• 230000000699 topical effect Effects 0.000 description 5
• CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 4
• WPJGHIVGAOVUAT-UHFFFAOYSA-N 1-(4-fluorophenyl)-2-oxopyridine-3-carboxylic acid Chemical compound O=C1C(C(=O)O)=CC=CN1C1=CC=C(F)C=C1 WPJGHIVGAOVUAT-UHFFFAOYSA-N 0.000 description 4
• ZMZGFLUUZLELNE-UHFFFAOYSA-N 2,3,5-triiodobenzoic acid Chemical compound OC(=O)C1=CC(I)=CC(I)=C1I ZMZGFLUUZLELNE-UHFFFAOYSA-N 0.000 description 4
• KVJJRUBYJAUYIT-UHFFFAOYSA-N 8-bromo-6-chloroimidazo[1,2-b]pyridazine;hydrochloride Chemical compound Cl.N1=C(Cl)C=C(Br)C2=NC=CN21 KVJJRUBYJAUYIT-UHFFFAOYSA-N 0.000 description 4
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
• 102000043136 MAP kinase family Human genes 0.000 description 4
• 108091054455 MAP kinase family Proteins 0.000 description 4
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
• 239000002253 acid Chemical group 0.000 description 4
• 239000013543 active substance Substances 0.000 description 4
• 125000002252 acyl group Chemical group 0.000 description 4
• 125000004419 alkynylene group Chemical group 0.000 description 4
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
• 239000003054 catalyst Substances 0.000 description 4
• 210000004027 cell Anatomy 0.000 description 4
• 229940079593 drug Drugs 0.000 description 4
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
• 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 4
• 239000012299 nitrogen atmosphere Substances 0.000 description 4
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
• 108090000765 processed proteins & peptides Proteins 0.000 description 4
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
• BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 4
• 230000002829 reductive effect Effects 0.000 description 4
• 238000010898 silica gel chromatography Methods 0.000 description 4
• 229910052717 sulfur Inorganic materials 0.000 description 4
• 229940124597 therapeutic agent Drugs 0.000 description 4
• 125000006168 tricyclic group Chemical group 0.000 description 4
• 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 4
• BOUIZPWBFIVJPD-UHFFFAOYSA-N 3h-1,2,4-triazin-4-amine Chemical compound NN1CN=NC=C1 BOUIZPWBFIVJPD-UHFFFAOYSA-N 0.000 description 3
• FGOWNGCSUSKHQI-UHFFFAOYSA-N 4-bromo-6-chloropyridazin-3-amine Chemical compound NC1=NN=C(Cl)C=C1Br FGOWNGCSUSKHQI-UHFFFAOYSA-N 0.000 description 3
• KPZCUKMHNDZCHV-UHFFFAOYSA-N 8-bromo-6-chloro-7-methylimidazo[1,2-b]pyridazine Chemical compound BrC1=C(C)C(Cl)=NN2C=CN=C21 KPZCUKMHNDZCHV-UHFFFAOYSA-N 0.000 description 3
• WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
• 239000005711 Benzoic acid Substances 0.000 description 3
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
• 108010037462 Cyclooxygenase 2 Proteins 0.000 description 3
• 108020004414 DNA Proteins 0.000 description 3
• 101150045041 ERG8 gene Proteins 0.000 description 3
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
• 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
• 229940124789 MK2 inhibitor Drugs 0.000 description 3
• 241001465754 Metazoa Species 0.000 description 3
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
• 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 3
• 102000001253 Protein Kinase Human genes 0.000 description 3
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
• 208000025865 Ulcer Diseases 0.000 description 3
• 229960000583 acetic acid Drugs 0.000 description 3
• 238000007792 addition Methods 0.000 description 3
• 150000001298 alcohols Chemical class 0.000 description 3
• 125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
• 125000003282 alkyl amino group Chemical group 0.000 description 3
• 125000004414 alkyl thio group Chemical group 0.000 description 3
• 235000010233 benzoic acid Nutrition 0.000 description 3
• 210000004369 blood Anatomy 0.000 description 3
• 239000008280 blood Substances 0.000 description 3
• 239000004202 carbamide Substances 0.000 description 3
• 239000000945 filler Substances 0.000 description 3
• 125000000592 heterocycloalkyl group Chemical group 0.000 description 3
• 230000007062 hydrolysis Effects 0.000 description 3
• 238000006460 hydrolysis reaction Methods 0.000 description 3
• 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
• 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
• 230000002401 inhibitory effect Effects 0.000 description 3
• 239000000314 lubricant Substances 0.000 description 3
• 125000001624 naphthyl group Chemical group 0.000 description 3
• 231100000252 nontoxic Toxicity 0.000 description 3
• 230000003000 nontoxic effect Effects 0.000 description 3
• 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 3
• 125000004043 oxo group Chemical group O=* 0.000 description 3
• 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 3
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
• 229920001223 polyethylene glycol Polymers 0.000 description 3
• 108060006633 protein kinase Proteins 0.000 description 3
• PJESVVYWPFAJCS-UHFFFAOYSA-N pyridazine-3-carbonitrile Chemical compound N#CC1=CC=CN=N1 PJESVVYWPFAJCS-UHFFFAOYSA-N 0.000 description 3
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical group COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
• 238000011160 research Methods 0.000 description 3
• 239000012047 saturated solution Substances 0.000 description 3
• 238000009097 single-agent therapy Methods 0.000 description 3
• 239000011734 sodium Substances 0.000 description 3
• 229910000104 sodium hydride Inorganic materials 0.000 description 3
• 229910052938 sodium sulfate Inorganic materials 0.000 description 3
• 235000011152 sodium sulphate Nutrition 0.000 description 3
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
• 239000003039 volatile agent Substances 0.000 description 3
• PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
• 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 2
• MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical group C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 description 2
• FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical compound C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 description 2
• MIRQIMKZPIQPDJ-UHFFFAOYSA-N 1-(4-fluorophenyl)-3-nitropyridin-2-one Chemical compound O=C1C([N+](=O)[O-])=CC=CN1C1=CC=C(F)C=C1 MIRQIMKZPIQPDJ-UHFFFAOYSA-N 0.000 description 2
• 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 2
• DOBWRWWGRZTEHG-UHFFFAOYSA-N 2-methylsulfanyl-3H-pyrazolo[1,5-a][1,3,5]triazin-4-one Chemical compound O=C1NC(SC)=NC2=CC=NN21 DOBWRWWGRZTEHG-UHFFFAOYSA-N 0.000 description 2
• NDKXOFBISSTBNJ-UHFFFAOYSA-N 3,8-dibromo-6-chloroimidazo[1,2-b]pyridazine Chemical compound N1=C(Cl)C=C(Br)C2=NC=C(Br)N21 NDKXOFBISSTBNJ-UHFFFAOYSA-N 0.000 description 2
• JKCRFGIYASUAHS-UHFFFAOYSA-N 3-[(6-chloro-7-methylimidazo[1,2-b]pyridazin-8-yl)amino]phenol Chemical compound CC=1C(Cl)=NN2C=CN=C2C=1NC1=CC=CC(O)=C1 JKCRFGIYASUAHS-UHFFFAOYSA-N 0.000 description 2
• CBDFJEBSCPTMJS-UHFFFAOYSA-N 3-amino-1-(4-fluorophenyl)pyridin-2-one Chemical compound O=C1C(N)=CC=CN1C1=CC=C(F)C=C1 CBDFJEBSCPTMJS-UHFFFAOYSA-N 0.000 description 2
• OVZAIVPSPAYSHC-UHFFFAOYSA-N 3-bromo-6-chloro-7-methyl-n-phenylimidazo[1,2-b]pyridazin-8-amine Chemical compound CC=1C(Cl)=NN2C(Br)=CN=C2C=1NC1=CC=CC=C1 OVZAIVPSPAYSHC-UHFFFAOYSA-N 0.000 description 2
• VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical group CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
• HTVUTSGDSONGNZ-UHFFFAOYSA-N 4-[(6-chloroimidazo[1,2-b]pyridazin-8-yl)amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=CC(Cl)=NN2C1=NC=C2 HTVUTSGDSONGNZ-UHFFFAOYSA-N 0.000 description 2
• JANJQHFWXHKUOB-UHFFFAOYSA-N 4-[(6-chloroimidazo[1,2-b]pyridazin-8-yl)amino]benzoyl chloride Chemical compound C1=CC(C(=O)Cl)=CC=C1NC1=CC(Cl)=NN2C1=NC=C2 JANJQHFWXHKUOB-UHFFFAOYSA-N 0.000 description 2
• HDZNBCJJXUDWCZ-UHFFFAOYSA-N 4-bromo-6-chloro-5-ethylpyridazin-3-amine Chemical compound CCC1=C(Cl)N=NC(N)=C1Br HDZNBCJJXUDWCZ-UHFFFAOYSA-N 0.000 description 2
• ZLYWLRPISFPECU-UHFFFAOYSA-N 4-bromo-6-chloro-5-methylpyridazin-3-amine Chemical compound CC1=C(Cl)N=NC(N)=C1Br ZLYWLRPISFPECU-UHFFFAOYSA-N 0.000 description 2
• HYHFXQKOPSIXFI-UHFFFAOYSA-N 4-bromo-6-chloro-5-phenylpyridazin-3-amine Chemical compound NC1=NN=C(Cl)C(C=2C=CC=CC=2)=C1Br HYHFXQKOPSIXFI-UHFFFAOYSA-N 0.000 description 2
• FKNQCJSGGFJEIZ-UHFFFAOYSA-N 4-methylpyridine Chemical compound CC1=CC=NC=C1 FKNQCJSGGFJEIZ-UHFFFAOYSA-N 0.000 description 2
• MQAWJHJFIZUKBS-UHFFFAOYSA-N 6,7,8-trichloroimidazo[1,2-b]pyridazine Chemical compound ClC1=C(Cl)C(Cl)=NN2C=CN=C21 MQAWJHJFIZUKBS-UHFFFAOYSA-N 0.000 description 2
• HSAHCMOZFNSMLH-UHFFFAOYSA-N 6-chloro-4-methylpyridazin-3-amine Chemical compound CC1=CC(Cl)=NN=C1N HSAHCMOZFNSMLH-UHFFFAOYSA-N 0.000 description 2
• HBZUZBUZANNSEN-UHFFFAOYSA-N 6-chloro-5-ethylpyridazin-3-amine Chemical compound CCC1=CC(N)=NN=C1Cl HBZUZBUZANNSEN-UHFFFAOYSA-N 0.000 description 2
• UWDLNRUFHRYMSE-UHFFFAOYSA-N 6-chloro-5-methylpyridazin-3-amine Chemical compound CC1=CC(N)=NN=C1Cl UWDLNRUFHRYMSE-UHFFFAOYSA-N 0.000 description 2
• QKOSEXWSPQSXFS-UHFFFAOYSA-N 6-chloro-5-phenylpyridazin-3-amine Chemical compound N1=NC(N)=CC(C=2C=CC=CC=2)=C1Cl QKOSEXWSPQSXFS-UHFFFAOYSA-N 0.000 description 2
• UZYJEPFFUHQZSZ-UHFFFAOYSA-N 6-chloro-8-(4-ethoxyanilino)imidazo[1,2-b]pyridazine-3-carbonitrile Chemical compound C1=CC(OCC)=CC=C1NC1=CC(Cl)=NN2C1=NC=C2C#N UZYJEPFFUHQZSZ-UHFFFAOYSA-N 0.000 description 2
• CRLUASFQJUPELM-UHFFFAOYSA-N 6-chloro-8-[n-[(4-methoxyphenyl)methyl]anilino]imidazo[1,2-b]pyridazine-3-carboxamide Chemical compound C1=CC(OC)=CC=C1CN(C=1C2=NC=C(N2N=C(Cl)C=1)C(N)=O)C1=CC=CC=C1 CRLUASFQJUPELM-UHFFFAOYSA-N 0.000 description 2
• UBAJZBLYEMGSFD-UHFFFAOYSA-N 8-bromo-6-chloro-2,3-dimethylimidazo[1,2-b]pyridazine Chemical compound BrC1=CC(Cl)=NN2C(C)=C(C)N=C21 UBAJZBLYEMGSFD-UHFFFAOYSA-N 0.000 description 2
• BLCVSIXYKZQWAR-UHFFFAOYSA-N 8-bromo-6-chloro-3-methylimidazo[1,2-b]pyridazine Chemical compound BrC1=CC(Cl)=NN2C(C)=CN=C21 BLCVSIXYKZQWAR-UHFFFAOYSA-N 0.000 description 2
• FOSNPUPZFUGOFB-UHFFFAOYSA-N 8-bromo-6-chloro-7-ethylimidazo[1,2-b]pyridazine Chemical compound BrC1=C(CC)C(Cl)=NN2C=CN=C21 FOSNPUPZFUGOFB-UHFFFAOYSA-N 0.000 description 2
• FBBGAGOKXBXVEK-UHFFFAOYSA-N 8-bromo-6-chloro-7-phenylimidazo[1,2-b]pyridazine Chemical compound ClC1=NN2C=CN=C2C(Br)=C1C1=CC=CC=C1 FBBGAGOKXBXVEK-UHFFFAOYSA-N 0.000 description 2
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
• VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
• PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
• 101100088077 Arabidopsis thaliana RKS1 gene Proteins 0.000 description 2
• 101100309711 Arabidopsis thaliana SD113 gene Proteins 0.000 description 2
• 101100053984 Arabidopsis thaliana ZRK1 gene Proteins 0.000 description 2
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
• 241000282472 Canis lupus familiaris Species 0.000 description 2
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
• XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
• 101100520660 Drosophila melanogaster Poc1 gene Proteins 0.000 description 2
• 101100291385 Drosophila melanogaster p38a gene Proteins 0.000 description 2
• 206010014824 Endotoxic shock Diseases 0.000 description 2
• 101150057924 Exoc2 gene Proteins 0.000 description 2
• 102100030843 Exocyst complex component 2 Human genes 0.000 description 2
• 102100022086 GRB2-related adapter protein 2 Human genes 0.000 description 2
• 102100040837 Galactoside alpha-(1,2)-fucosyltransferase 2 Human genes 0.000 description 2
• 102000005623 HSP27 Heat-Shock Proteins Human genes 0.000 description 2
• 108010045100 HSP27 Heat-Shock Proteins Proteins 0.000 description 2
• 102100035108 High affinity nerve growth factor receptor Human genes 0.000 description 2
• 101000893710 Homo sapiens Galactoside alpha-(1,2)-fucosyltransferase 2 Proteins 0.000 description 2
• 101000596894 Homo sapiens High affinity nerve growth factor receptor Proteins 0.000 description 2
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
• 229930195725 Mannitol Natural products 0.000 description 2
• 206010027480 Metastatic malignant melanoma Diseases 0.000 description 2
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
• HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
• SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• 239000004793 Polystyrene Substances 0.000 description 2
• 101150110070 SEC5 gene Proteins 0.000 description 2
• 101100520662 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PBA1 gene Proteins 0.000 description 2
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
• 101000882403 Staphylococcus aureus Enterotoxin type C-2 Proteins 0.000 description 2
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 2
• DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
• 230000004913 activation Effects 0.000 description 2
• OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
• 235000010443 alginic acid Nutrition 0.000 description 2
• 229920000615 alginic acid Polymers 0.000 description 2
• 150000001447 alkali salts Chemical class 0.000 description 2
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
• 125000003277 amino group Chemical group 0.000 description 2
• 235000019270 ammonium chloride Nutrition 0.000 description 2
• 239000000908 ammonium hydroxide Substances 0.000 description 2
• ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 2
• 150000001448 anilines Chemical class 0.000 description 2
• 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
• 239000008346 aqueous phase Substances 0.000 description 2
• 125000003710 aryl alkyl group Chemical group 0.000 description 2
• 239000012298 atmosphere Substances 0.000 description 2
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
• 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 2
• PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 2
• WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
• 239000011230 binding agent Substances 0.000 description 2
• 230000037396 body weight Effects 0.000 description 2
• 238000009835 boiling Methods 0.000 description 2
• 210000000988 bone and bone Anatomy 0.000 description 2
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
• 229910052794 bromium Inorganic materials 0.000 description 2
• 150000001649 bromium compounds Chemical class 0.000 description 2
• 239000011575 calcium Substances 0.000 description 2
• 125000002837 carbocyclic group Chemical group 0.000 description 2
• 229910002091 carbon monoxide Inorganic materials 0.000 description 2
• 125000005518 carboxamido group Chemical group 0.000 description 2
• 239000001768 carboxy methyl cellulose Substances 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 239000006285 cell suspension Substances 0.000 description 2
• 238000004587 chromatography analysis Methods 0.000 description 2
• 229940126214 compound 3 Drugs 0.000 description 2
• 229940125898 compound 5 Drugs 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 229920001577 copolymer Polymers 0.000 description 2
• 125000004122 cyclic group Chemical group 0.000 description 2
• 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
• XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
• ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
• 239000012153 distilled water Substances 0.000 description 2
• 239000003480 eluent Substances 0.000 description 2
• 239000003623 enhancer Substances 0.000 description 2
• 239000000284 extract Substances 0.000 description 2
• GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 2
• 239000011888 foil Substances 0.000 description 2
• 125000004438 haloalkoxy group Chemical group 0.000 description 2
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• 150000003840 hydrochlorides Chemical class 0.000 description 2
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
• YCLUMBJQKREDFM-UHFFFAOYSA-N imidazo[1,2-b]pyridazine-3-carboxamide Chemical compound C1=CC=NN2C(C(=O)N)=CN=C21 YCLUMBJQKREDFM-UHFFFAOYSA-N 0.000 description 2
• 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
• 238000011534 incubation Methods 0.000 description 2
• 230000001939 inductive effect Effects 0.000 description 2
• 230000002757 inflammatory effect Effects 0.000 description 2
• 230000028709 inflammatory response Effects 0.000 description 2
• 239000003112 inhibitor Substances 0.000 description 2
• 238000002347 injection Methods 0.000 description 2
• 239000007924 injection Substances 0.000 description 2
• 150000004694 iodide salts Chemical class 0.000 description 2
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 239000000594 mannitol Substances 0.000 description 2
• 235000010355 mannitol Nutrition 0.000 description 2
• 230000001404 mediated effect Effects 0.000 description 2
• 230000002503 metabolic effect Effects 0.000 description 2
• 208000021039 metastatic melanoma Diseases 0.000 description 2
• 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
• 239000008108 microcrystalline cellulose Substances 0.000 description 2
• 229940016286 microcrystalline cellulose Drugs 0.000 description 2
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
• 150000002823 nitrates Chemical class 0.000 description 2
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
• 239000003921 oil Substances 0.000 description 2
• 239000002674 ointment Substances 0.000 description 2
• CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
• 239000001301 oxygen Substances 0.000 description 2
• 125000004430 oxygen atom Chemical group O* 0.000 description 2
• 230000007170 pathology Effects 0.000 description 2
• DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 2
• 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
• 235000021317 phosphate Nutrition 0.000 description 2
• 230000026731 phosphorylation Effects 0.000 description 2
• 238000006366 phosphorylation reaction Methods 0.000 description 2
• 229920002223 polystyrene Polymers 0.000 description 2
• 229910052700 potassium Inorganic materials 0.000 description 2
• 229910000027 potassium carbonate Inorganic materials 0.000 description 2
• FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
• 239000000843 powder Substances 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• 150000003180 prostaglandins Chemical class 0.000 description 2
• 230000002685 pulmonary effect Effects 0.000 description 2
• 125000004942 pyridazin-6-yl group Chemical group N1=NC=CC=C1* 0.000 description 2
• 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
• 239000011535 reaction buffer Substances 0.000 description 2
• 102000005962 receptors Human genes 0.000 description 2
• 108020003175 receptors Proteins 0.000 description 2
• 238000010992 reflux Methods 0.000 description 2
• 230000004044 response Effects 0.000 description 2
• 150000003873 salicylate salts Chemical class 0.000 description 2
• SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
• 229960002930 sirolimus Drugs 0.000 description 2
• 239000012312 sodium hydride Substances 0.000 description 2
• 239000012453 solvate Substances 0.000 description 2
• 239000003381 stabilizer Substances 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 239000000126 substance Substances 0.000 description 2
• 229940124530 sulfonamide Drugs 0.000 description 2
• 150000003456 sulfonamides Chemical class 0.000 description 2
• 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 2
• 239000000829 suppository Substances 0.000 description 2
• 239000000375 suspending agent Substances 0.000 description 2
• 238000013268 sustained release Methods 0.000 description 2
• 239000012730 sustained-release form Substances 0.000 description 2
• 208000024891 symptom Diseases 0.000 description 2
• 239000003826 tablet Substances 0.000 description 2
• 238000001665 trituration Methods 0.000 description 2
• 238000011144 upstream manufacturing Methods 0.000 description 2
• 230000003612 virological effect Effects 0.000 description 2
• CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 2
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
• KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
• SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
• NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
• KCZIUKYAJJEIQG-UHFFFAOYSA-N 1,3,5-triazin-2-amine Chemical compound NC1=NC=NC=N1 KCZIUKYAJJEIQG-UHFFFAOYSA-N 0.000 description 1
• CBCKQZAAMUWICA-UHFFFAOYSA-N 1,4-phenylenediamine Chemical compound NC1=CC=C(N)C=C1 CBCKQZAAMUWICA-UHFFFAOYSA-N 0.000 description 1
• IDPURXSQCKYKIJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 description 1
• ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
• HARWNWOLWMTQCC-UHFFFAOYSA-N 1-benzylpiperidin-3-amine Chemical compound C1C(N)CCCN1CC1=CC=CC=C1 HARWNWOLWMTQCC-UHFFFAOYSA-N 0.000 description 1
• VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
• VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical class CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
• LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
• HIZMJYQEHFJWQY-UHFFFAOYSA-N 1-pyridin-4-ylethanamine Chemical compound CC(N)C1=CC=NC=C1 HIZMJYQEHFJWQY-UHFFFAOYSA-N 0.000 description 1
• JVVRJMXHNUAPHW-UHFFFAOYSA-N 1h-pyrazol-5-amine Chemical compound NC=1C=CNN=1 JVVRJMXHNUAPHW-UHFFFAOYSA-N 0.000 description 1
• 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 1
• ODUZJBKKYBQIBX-UHFFFAOYSA-N 2,6-difluoroaniline Chemical compound NC1=C(F)C=CC=C1F ODUZJBKKYBQIBX-UHFFFAOYSA-N 0.000 description 1
• HOMVALPRPUJYMB-UHFFFAOYSA-N 2-(4-aminophenyl)imidazo[1,2-b]pyridazine-6,8-diamine Chemical compound C1=CC(N)=CC=C1C1=CN(N=C(N)C=C2N)C2=N1 HOMVALPRPUJYMB-UHFFFAOYSA-N 0.000 description 1
• GQLDSDBFDCVZHR-UHFFFAOYSA-N 2-[(4-methoxyphenyl)methyl]imidazo[1,2-b]pyridazine-6,8-diamine Chemical compound C1=CC(OC)=CC=C1CC1=CN(N=C(N)C=C2N)C2=N1 GQLDSDBFDCVZHR-UHFFFAOYSA-N 0.000 description 1
• UKFTXWKNVSVVCJ-UHFFFAOYSA-N 2-[(6-hydrazinylpyridazin-3-yl)-(2-hydroxyethyl)amino]ethanol;hydron;dichloride Chemical class Cl.Cl.NNC1=CC=C(N(CCO)CCO)N=N1 UKFTXWKNVSVVCJ-UHFFFAOYSA-N 0.000 description 1
• USYKAPHTJDDRLV-UHFFFAOYSA-N 2-chloro-1,1-dimethoxypropane Chemical compound COC(OC)C(C)Cl USYKAPHTJDDRLV-UHFFFAOYSA-N 0.000 description 1
• 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
• BNXBOEKNXAOOCP-UHFFFAOYSA-N 2-cyclohexylbenzamide Chemical compound NC(=O)C1=CC=CC=C1C1CCCCC1 BNXBOEKNXAOOCP-UHFFFAOYSA-N 0.000 description 1
• PQCVYHSKABCYON-UHFFFAOYSA-N 2-oxo-1h-pyridine-3-carboxamide Chemical compound NC(=O)C1=CC=CN=C1O PQCVYHSKABCYON-UHFFFAOYSA-N 0.000 description 1
• GTKIGDZXPDCIKR-UHFFFAOYSA-N 2-phenylbenzamide Chemical compound NC(=O)C1=CC=CC=C1C1=CC=CC=C1 GTKIGDZXPDCIKR-UHFFFAOYSA-N 0.000 description 1
• 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
• WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
• NONHPJMELXNBOJ-UHFFFAOYSA-N 2-phenylimidazo[1,2-b]pyridazin-8-amine Chemical compound C1(=CC=CC=C1)C=1N=C2N(N=CC=C2N)C=1 NONHPJMELXNBOJ-UHFFFAOYSA-N 0.000 description 1
• YSSDVMSKYUWULF-UHFFFAOYSA-N 2-sulfanylidene-6h-pyrazolo[1,5-a][1,3,5]triazin-4-one Chemical compound O=C1NC(=S)N=C2C=CNN12 YSSDVMSKYUWULF-UHFFFAOYSA-N 0.000 description 1
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
• DTXVKPOKPFWSFF-UHFFFAOYSA-N 3(S)-hydroxy-13-cis-eicosenoyl-CoA Chemical compound NC1=CC=C(Cl)N=N1 DTXVKPOKPFWSFF-UHFFFAOYSA-N 0.000 description 1
• 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 description 1
• YKUMFVUOUWBXTB-UHFFFAOYSA-N 3,6-dichloro-4-ethylpyridazine Chemical compound CCC1=CC(Cl)=NN=C1Cl YKUMFVUOUWBXTB-UHFFFAOYSA-N 0.000 description 1
• ROYHWGZNGMXQEU-UHFFFAOYSA-N 3,6-dichloro-4-methylpyridazine Chemical compound CC1=CC(Cl)=NN=C1Cl ROYHWGZNGMXQEU-UHFFFAOYSA-N 0.000 description 1
• GUSWJGOYDXFJSI-UHFFFAOYSA-N 3,6-dichloropyridazine Chemical compound ClC1=CC=C(Cl)N=N1 GUSWJGOYDXFJSI-UHFFFAOYSA-N 0.000 description 1
• YDDOBULFNFDULV-UHFFFAOYSA-N 3,8-dibromo-6-chloro-7-methylimidazo[1,2-b]pyridazine Chemical compound BrC1=C(C)C(Cl)=NN2C(Br)=CN=C21 YDDOBULFNFDULV-UHFFFAOYSA-N 0.000 description 1
• OIMRLHCSLQUXLL-UHFFFAOYSA-N 3-chlorobutan-2-one Chemical compound CC(Cl)C(C)=O OIMRLHCSLQUXLL-UHFFFAOYSA-N 0.000 description 1
• NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
• 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
• 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
• 125000006305 3-iodophenyl group Chemical group [H]C1=C([H])C(I)=C([H])C(*)=C1[H] 0.000 description 1
• BOAFCICMVMFLIT-UHFFFAOYSA-N 3-nitro-1h-pyridin-2-one Chemical compound OC1=NC=CC=C1[N+]([O-])=O BOAFCICMVMFLIT-UHFFFAOYSA-N 0.000 description 1
• IGPFOKFDBICQMC-UHFFFAOYSA-N 3-phenylmethoxyaniline Chemical compound NC1=CC=CC(OCC=2C=CC=CC=2)=C1 IGPFOKFDBICQMC-UHFFFAOYSA-N 0.000 description 1
• XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical class OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
• QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
• PDFYLKPBYWPEDQ-UHFFFAOYSA-N 4-chloro-2-methylsulfanylpyrazolo[1,5-a][1,3,5]triazine Chemical compound N1=C(SC)N=C(Cl)N2N=CC=C21 PDFYLKPBYWPEDQ-UHFFFAOYSA-N 0.000 description 1
• MCNQUWLLXZZZAC-UHFFFAOYSA-N 4-cyano-1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-n-piperidin-1-ylpyrazole-3-carboxamide Chemical compound C1=CC(OC)=CC=C1C1=C(C#N)C(C(=O)NN2CCCCC2)=NN1C1=CC=C(Cl)C=C1Cl MCNQUWLLXZZZAC-UHFFFAOYSA-N 0.000 description 1
• 125000004860 4-ethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])C([H])([H])[H] 0.000 description 1
• KRZCOLNOCZKSDF-UHFFFAOYSA-N 4-fluoroaniline Chemical compound NC1=CC=C(F)C=C1 KRZCOLNOCZKSDF-UHFFFAOYSA-N 0.000 description 1
• LBUNNMJLXWQQBY-UHFFFAOYSA-N 4-fluorophenylboronic acid Chemical compound OB(O)C1=CC=C(F)C=C1 LBUNNMJLXWQQBY-UHFFFAOYSA-N 0.000 description 1
• CRLGEVRXLCFUBH-UHFFFAOYSA-N 4-n-imidazo[1,2-b]pyridazin-8-ylbenzene-1,4-diamine Chemical compound C1=CC(N)=CC=C1NC1=CC=NN2C1=NC=C2 CRLGEVRXLCFUBH-UHFFFAOYSA-N 0.000 description 1
• TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 1
• GIJMYAWMNQEVSX-UHFFFAOYSA-N 5-bromo-3-chloro-1,6-dihydropyridazin-6-amine Chemical compound NC1NN=C(Cl)C=C1Br GIJMYAWMNQEVSX-UHFFFAOYSA-N 0.000 description 1
• CBTCXKMNDBPVLQ-UHFFFAOYSA-N 5-chloro-4-ethylpyridazin-3-amine Chemical compound CCC1=C(N)N=NC=C1Cl CBTCXKMNDBPVLQ-UHFFFAOYSA-N 0.000 description 1
• JYIBKUMVBKZIHJ-UHFFFAOYSA-N 6,8-dichloro-3-methylimidazo[1,2-b]pyridazine Chemical compound ClC1=CC(Cl)=NN2C(C)=CN=C21 JYIBKUMVBKZIHJ-UHFFFAOYSA-N 0.000 description 1
• RXHWFBVEDHZUGB-UHFFFAOYSA-N 6-chloro-4-ethylpyridazin-3-amine Chemical compound CCC1=CC(Cl)=NN=C1N RXHWFBVEDHZUGB-UHFFFAOYSA-N 0.000 description 1
• BOCWQVXYJIOALL-UHFFFAOYSA-N 7,8-dichloro-5h-imidazo[1,2-b]pyridazin-6-one Chemical compound ClC1=C(Cl)C(O)=NN2C=CN=C21 BOCWQVXYJIOALL-UHFFFAOYSA-N 0.000 description 1
• WXWFQLXRQAUZTO-UHFFFAOYSA-N 8-bromo-6-chloro-3-fluoroimidazo[1,2-b]pyridazine Chemical compound BrC1=CC(Cl)=NN2C(F)=CN=C21 WXWFQLXRQAUZTO-UHFFFAOYSA-N 0.000 description 1
• DMTCIDIMFLARCR-UHFFFAOYSA-N 8-bromo-6-chloro-7-methylimidazo[1,2-b]pyridazine;hydrochloride Chemical compound Cl.BrC1=C(C)C(Cl)=NN2C=CN=C21 DMTCIDIMFLARCR-UHFFFAOYSA-N 0.000 description 1
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
• 102100038079 AP2-associated protein kinase 1 Human genes 0.000 description 1
• 241000772991 Aira Species 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 101100058598 Arabidopsis thaliana BPM1 gene Proteins 0.000 description 1
• 101100453931 Arabidopsis thaliana KINB3 gene Proteins 0.000 description 1
• 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 1
• 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 208000020084 Bone disease Diseases 0.000 description 1
• 101000908384 Bos taurus Dipeptidyl peptidase 4 Proteins 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• 102100031102 C-C motif chemokine 4 Human genes 0.000 description 1
• 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
• 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
• GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 206010007559 Cardiac failure congestive Diseases 0.000 description 1
• 102000014914 Carrier Proteins Human genes 0.000 description 1
• 229930186147 Cephalosporin Natural products 0.000 description 1
• 208000035473 Communicable disease Diseases 0.000 description 1
• 229920000858 Cyclodextrin Polymers 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
• 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
• XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
• 206010013710 Drug interaction Diseases 0.000 description 1
• 102100023275 Dual specificity mitogen-activated protein kinase kinase 3 Human genes 0.000 description 1
• 102100023401 Dual specificity mitogen-activated protein kinase kinase 6 Human genes 0.000 description 1
• 101710140859 E3 ubiquitin ligase TRAF3IP2 Proteins 0.000 description 1
• 102100026620 E3 ubiquitin ligase TRAF3IP2 Human genes 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 241000713730 Equine infectious anemia virus Species 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 208000009329 Graft vs Host Disease Diseases 0.000 description 1
• 206010019280 Heart failures Diseases 0.000 description 1
• 102100027421 Heat shock cognate 71 kDa protein Human genes 0.000 description 1
• 102100039121 Histone-lysine N-methyltransferase MECOM Human genes 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000742699 Homo sapiens AP2-associated protein kinase 1 Proteins 0.000 description 1
• 101001115394 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 3 Proteins 0.000 description 1
• 101000624426 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 6 Proteins 0.000 description 1
• 101001033728 Homo sapiens Histone-lysine N-methyltransferase MECOM Proteins 0.000 description 1
• 101000854346 Homo sapiens Inactive ribonuclease-like protein 9 Proteins 0.000 description 1
• 101001059427 Homo sapiens MAP/microtubule affinity-regulating kinase 4 Proteins 0.000 description 1
• 101000633302 Homo sapiens Nicotinamide riboside kinase 1 Proteins 0.000 description 1
• 101001059443 Homo sapiens Serine/threonine-protein kinase MARK1 Proteins 0.000 description 1
• 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 102100036004 Inactive ribonuclease-like protein 9 Human genes 0.000 description 1
• 102000003814 Interleukin-10 Human genes 0.000 description 1
• 108090000174 Interleukin-10 Proteins 0.000 description 1
• 108010044467 Isoenzymes Proteins 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• 102100027105 Lymphocyte-specific protein 1 Human genes 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 102100028913 MAP/microtubule affinity-regulating kinase 4 Human genes 0.000 description 1
• 241001024304 Mino Species 0.000 description 1
• 241000699666 Mus <mouse, genus> Species 0.000 description 1
• 101000777470 Mus musculus C-C motif chemokine 4 Proteins 0.000 description 1
• OHLUUHNLEMFGTQ-UHFFFAOYSA-N N-methylacetamide Chemical compound CNC(C)=O OHLUUHNLEMFGTQ-UHFFFAOYSA-N 0.000 description 1
• IZWNUNUHGIYTIL-UFXILDGNSA-N N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)N)N Chemical compound N[C@@H]1CC[C@H](CC1)C1(C=C(C=2N(N1)C=CN=2)N)N IZWNUNUHGIYTIL-UFXILDGNSA-N 0.000 description 1
• QCNFWNHIDFTFMO-ZKCHVHJHSA-N N[C@H](CC1)CC[C@@H]1C(N=C1C(N)=C2)=CN1N=C2N Chemical compound N[C@H](CC1)CC[C@@H]1C(N=C1C(N)=C2)=CN1N=C2N QCNFWNHIDFTFMO-ZKCHVHJHSA-N 0.000 description 1
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
• 102100029562 Nicotinamide riboside kinase 1 Human genes 0.000 description 1
• 108091028043 Nucleic acid sequence Proteins 0.000 description 1
• 101150024689 OST3 gene Proteins 0.000 description 1
• 241000497429 Obus Species 0.000 description 1
• 239000005642 Oleic acid Substances 0.000 description 1
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
• 108091034117 Oligonucleotide Proteins 0.000 description 1
• 101150071746 Pbsn gene Proteins 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
• 241000577218 Phenes Species 0.000 description 1
• 239000004698 Polyethylene Substances 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 208000006994 Precancerous Conditions Diseases 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
• 101710092489 Protein kinase 2 Proteins 0.000 description 1
• 235000014443 Pyrus communis Nutrition 0.000 description 1
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
• 206010038997 Retroviral infections Diseases 0.000 description 1
• 229920002684 Sepharose Polymers 0.000 description 1
• 102100028921 Serine/threonine-protein kinase MARK1 Human genes 0.000 description 1
• 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 1
• 101150019400 TMK1 gene Proteins 0.000 description 1
• 108090000922 TNF receptor-associated factor 3 Proteins 0.000 description 1
• 239000004809 Teflon Substances 0.000 description 1
• 229920006362 Teflon® Polymers 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
• 241000927721 Tritia Species 0.000 description 1
• 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
• 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• JVVXZOOGOGPDRZ-SLFFLAALSA-N [(1R,4aS,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthren-1-yl]methanamine Chemical compound NC[C@]1(C)CCC[C@]2(C)C3=CC=C(C(C)C)C=C3CC[C@H]21 JVVXZOOGOGPDRZ-SLFFLAALSA-N 0.000 description 1
• DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
• MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 1
• 229960004748 abacavir Drugs 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 150000001242 acetic acid derivatives Chemical class 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 150000008043 acidic salts Chemical class 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 125000004442 acylamino group Chemical group 0.000 description 1
• 230000000996 additive effect Effects 0.000 description 1
• 229960005305 adenosine Drugs 0.000 description 1
• WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 238000001261 affinity purification Methods 0.000 description 1
• 238000007605 air drying Methods 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
• 125000006177 alkyl benzyl group Chemical group 0.000 description 1
• 150000001350 alkyl halides Chemical class 0.000 description 1
• AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
• 125000003368 amide group Chemical group 0.000 description 1
• 150000001408 amides Chemical class 0.000 description 1
• 125000000747 amidyl group Chemical group [H][N-]* 0.000 description 1
• 125000000539 amino acid group Chemical group 0.000 description 1
• 150000001413 amino acids Chemical class 0.000 description 1
• 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
• 229910021529 ammonia Inorganic materials 0.000 description 1
• 229910001870 ammonium persulfate Inorganic materials 0.000 description 1
• 150000003863 ammonium salts Chemical class 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 229940124599 anti-inflammatory drug Drugs 0.000 description 1
• 230000001028 anti-proliverative effect Effects 0.000 description 1
• 230000002785 anti-thrombosis Effects 0.000 description 1
• 239000003443 antiviral agent Substances 0.000 description 1
• 239000012736 aqueous medium Substances 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 229910052786 argon Inorganic materials 0.000 description 1
• 150000001502 aryl halides Chemical class 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical class N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
• 229960002170 azathioprine Drugs 0.000 description 1
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
• 125000002393 azetidinyl group Chemical group 0.000 description 1
• 229910052788 barium Inorganic materials 0.000 description 1
• DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
• 239000003637 basic solution Substances 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
• 125000005605 benzo group Chemical group 0.000 description 1
• 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
• 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 235000019445 benzyl alcohol Nutrition 0.000 description 1
• DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
• FYGDTMLNYKFZSV-CSHPIKHBSA-N beta-cellotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-CSHPIKHBSA-N 0.000 description 1
• DHCLVCXQIBBOPH-UHFFFAOYSA-N beta-glycerol phosphate Natural products OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 1
• GHRQXJHBXKYCLZ-UHFFFAOYSA-L beta-glycerolphosphate Chemical compound [Na+].[Na+].CC(CO)OOP([O-])([O-])=O GHRQXJHBXKYCLZ-UHFFFAOYSA-L 0.000 description 1
• 108091008324 binding proteins Proteins 0.000 description 1
• 239000012867 bioactive agent Substances 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 235000010290 biphenyl Nutrition 0.000 description 1
• 239000004305 biphenyl Substances 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
• 150000001642 boronic acid derivatives Chemical class 0.000 description 1
• 125000001246 bromo group Chemical group Br* 0.000 description 1
• 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229930194791 calphostin Natural products 0.000 description 1
• 201000011510 cancer Diseases 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
• 150000003857 carboxamides Chemical class 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 238000005341 cation exchange Methods 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
• 229960000590 celecoxib Drugs 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 235000010980 cellulose Nutrition 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 229940124587 cephalosporin Drugs 0.000 description 1
• 150000001780 cephalosporins Chemical class 0.000 description 1
• OOXVDMMAVZXHFW-UHFFFAOYSA-N chembl2402380 Chemical compound O=C1NC(=S)NC2=CC=NN12 OOXVDMMAVZXHFW-UHFFFAOYSA-N 0.000 description 1
• 238000001311 chemical methods and process Methods 0.000 description 1
• 125000001309 chloro group Chemical group Cl* 0.000 description 1
• OTAFHZMPRISVEM-UHFFFAOYSA-N chromone Chemical compound C1=CC=C2C(=O)C=COC2=C1 OTAFHZMPRISVEM-UHFFFAOYSA-N 0.000 description 1
• 208000037976 chronic inflammation Diseases 0.000 description 1
• 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
• 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
• 150000001860 citric acid derivatives Chemical class 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 238000004440 column chromatography Methods 0.000 description 1
• 238000004891 communication Methods 0.000 description 1
• OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 1
• 239000003246 corticosteroid Substances 0.000 description 1
• 229960001334 corticosteroids Drugs 0.000 description 1
• 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 125000000392 cycloalkenyl group Chemical group 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 229940097362 cyclodextrins Drugs 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
• NLUNLVTVUDIHFE-UHFFFAOYSA-N cyclooctylcyclooctane Chemical group C1CCCCCCC1C1CCCCCCC1 NLUNLVTVUDIHFE-UHFFFAOYSA-N 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 238000002716 delivery method Methods 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 230000001066 destructive effect Effects 0.000 description 1
• 229960003957 dexamethasone Drugs 0.000 description 1
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
• 150000008050 dialkyl sulfates Chemical class 0.000 description 1
• MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
• NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
• 229940038472 dicalcium phosphate Drugs 0.000 description 1
• 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
• 102000038379 digestive enzymes Human genes 0.000 description 1
• 108091007734 digestive enzymes Proteins 0.000 description 1
• 125000004611 dihydroisoindolyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
• 125000005044 dihydroquinolinyl group Chemical group N1(CC=CC2=CC=CC=C12)* 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
• GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
• CZZYITDELCSZES-UHFFFAOYSA-N diphenylmethane Chemical compound C=1C=CC=CC=1CC1=CC=CC=C1 CZZYITDELCSZES-UHFFFAOYSA-N 0.000 description 1
• 208000037765 diseases and disorders Diseases 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• BOBUBHOXRCYKLI-UHFFFAOYSA-N ditert-butyl(cyclopenta-2,4-dien-1-yl)phosphane;iron(2+);(2,3,4,5-tetraphenylcyclopenta-1,4-dien-1-yl)benzene Chemical compound [Fe+2].CC(C)(C)P(C(C)(C)C)C1=CC=C[CH-]1.C1=CC=CC=C1C1=C(C=2C=CC=CC=2)[C-](C=2C=CC=CC=2)C(C=2C=CC=CC=2)=C1C1=CC=CC=C1 BOBUBHOXRCYKLI-UHFFFAOYSA-N 0.000 description 1
• 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 238000001035 drying Methods 0.000 description 1
• 208000001321 ectrodactyly, ectodermal dysplasia, and cleft lip-palate syndrome 1 Diseases 0.000 description 1
• 239000012636 effector Substances 0.000 description 1
• 239000002532 enzyme inhibitor Substances 0.000 description 1
• 229940125532 enzyme inhibitor Drugs 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
• BDTDECDAHYOJRO-UHFFFAOYSA-N ethyl n-(sulfanylidenemethylidene)carbamate Chemical compound CCOC(=O)N=C=S BDTDECDAHYOJRO-UHFFFAOYSA-N 0.000 description 1
• 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
• 230000005284 excitation Effects 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 239000012091 fetal bovine serum Substances 0.000 description 1
• 238000003818 flash chromatography Methods 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 235000019634 flavors Nutrition 0.000 description 1
• 125000001153 fluoro group Chemical group F* 0.000 description 1
• 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 238000001640 fractional crystallisation Methods 0.000 description 1
• 239000012458 free base Substances 0.000 description 1
• 238000004108 freeze drying Methods 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• 102000037865 fusion proteins Human genes 0.000 description 1
• 108020001507 fusion proteins Proteins 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 238000002523 gelfiltration Methods 0.000 description 1
• 239000012362 glacial acetic acid Substances 0.000 description 1
• 239000003862 glucocorticoid Substances 0.000 description 1
• 150000002314 glycerols Chemical class 0.000 description 1
• 150000002315 glycerophosphates Chemical class 0.000 description 1
• 208000024908 graft versus host disease Diseases 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 239000001963 growth medium Substances 0.000 description 1
• 229960002706 gusperimus Drugs 0.000 description 1
• 229940093915 gynecological organic acid Drugs 0.000 description 1
• 150000004820 halides Chemical class 0.000 description 1
• MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical class CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
• 125000004404 heteroalkyl group Chemical group 0.000 description 1
• FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical class CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
• 229960001680 ibuprofen Drugs 0.000 description 1
• VTVRXITWWZGKHV-UHFFFAOYSA-N imidazo[1,2-b]pyridazine Chemical compound N1=CC=CC2=NC=CN21 VTVRXITWWZGKHV-UHFFFAOYSA-N 0.000 description 1
• 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
• 125000002636 imidazolinyl group Chemical group 0.000 description 1
• 208000026278 immune system disease Diseases 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
• 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
• 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
• 125000001041 indolyl group Chemical group 0.000 description 1
• 239000012678 infectious agent Substances 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 229940076144 interleukin-10 Drugs 0.000 description 1
• 239000000543 intermediate Substances 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 230000004068 intracellular signaling Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 125000002346 iodo group Chemical group I* 0.000 description 1
• INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
• 239000003456 ion exchange resin Substances 0.000 description 1
• 229920003303 ion-exchange polymer Polymers 0.000 description 1
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
• 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
• 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
• 125000001786 isothiazolyl group Chemical group 0.000 description 1
• 125000003971 isoxazolinyl group Chemical group 0.000 description 1
• 125000000842 isoxazolyl group Chemical group 0.000 description 1
• 150000003893 lactate salts Chemical class 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 238000004811 liquid chromatography Methods 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• 108010040838 lymphocyte-specific protein p50 Proteins 0.000 description 1
• 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
• 159000000003 magnesium salts Chemical class 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 229940057948 magnesium stearate Drugs 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• 150000002688 maleic acid derivatives Chemical class 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 235000013372 meat Nutrition 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 108020004999 messenger RNA Proteins 0.000 description 1
• LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
• 229940098779 methanesulfonic acid Drugs 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
• GJVZWOMUTYNUCE-UHFFFAOYSA-N methyl 2-oxopyran-3-carboxylate Chemical compound COC(=O)C1=CC=COC1=O GJVZWOMUTYNUCE-UHFFFAOYSA-N 0.000 description 1
• QKDSOVIFMAKEOM-UHFFFAOYSA-N methyl 5-(4-fluorophenyl)-6-oxocyclohexa-1,3-diene-1-carboxylate Chemical compound O=C1C(C(=O)OC)=CC=CC1C1=CC=C(F)C=C1 QKDSOVIFMAKEOM-UHFFFAOYSA-N 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 235000010981 methylcellulose Nutrition 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 239000003226 mitogen Substances 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 210000004400 mucous membrane Anatomy 0.000 description 1
• 230000035772 mutation Effects 0.000 description 1
• 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• UZPYLQMILDGYPO-UHFFFAOYSA-N n-(2-pyridin-4-ylethyl)benzamide Chemical compound C=1C=CC=CC=1C(=O)NCCC1=CC=NC=C1 UZPYLQMILDGYPO-UHFFFAOYSA-N 0.000 description 1
• HUTPNBKMFJRRCW-UHFFFAOYSA-N n-(6-chloroimidazo[1,2-b]pyridazin-8-yl)benzenesulfonamide Chemical compound C12=NC=CN2N=C(Cl)C=C1NS(=O)(=O)C1=CC=CC=C1 HUTPNBKMFJRRCW-UHFFFAOYSA-N 0.000 description 1
• LGTPQVBRVVRWDX-UHFFFAOYSA-N n-(cyclohexylmethyl)benzamide Chemical compound C=1C=CC=CC=1C(=O)NCC1CCCCC1 LGTPQVBRVVRWDX-UHFFFAOYSA-N 0.000 description 1
• GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 1
• IDINUJSAMVOPCM-INIZCTEOSA-N n-[(1s)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxy-2-oxoethyl]-7-(diaminomethylideneamino)heptanamide Chemical compound NCCCNCCCCNC(=O)[C@H](O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-INIZCTEOSA-N 0.000 description 1
• WRDZMZGYHVUYRU-UHFFFAOYSA-N n-[(4-methoxyphenyl)methyl]aniline Chemical compound C1=CC(OC)=CC=C1CNC1=CC=CC=C1 WRDZMZGYHVUYRU-UHFFFAOYSA-N 0.000 description 1
• ONBHMNXIFRLXBA-UHFFFAOYSA-N n-[1-(4-fluorophenyl)-2-oxopyridin-3-yl]benzamide Chemical compound C1=CC(F)=CC=C1N1C(=O)C(NC(=O)C=2C=CC=CC=2)=CC=C1 ONBHMNXIFRLXBA-UHFFFAOYSA-N 0.000 description 1
• FVLVBVSILSHUAF-UHFFFAOYSA-N n-benzyl-3,5-dimethyl-n-propan-2-ylbenzamide Chemical compound C=1C(C)=CC(C)=CC=1C(=O)N(C(C)C)CC1=CC=CC=C1 FVLVBVSILSHUAF-UHFFFAOYSA-N 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical class C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
• 238000006386 neutralization reaction Methods 0.000 description 1
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
• 231100000344 non-irritating Toxicity 0.000 description 1
• 230000005937 nuclear translocation Effects 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
• 230000000771 oncological effect Effects 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• 229940046781 other immunosuppressants in atc Drugs 0.000 description 1
• 125000001715 oxadiazolyl group Chemical group 0.000 description 1
• 150000003891 oxalate salts Chemical class 0.000 description 1
• 125000000160 oxazolidinyl group Chemical group 0.000 description 1
• 125000002971 oxazolyl group Chemical group 0.000 description 1
• 125000003566 oxetanyl group Chemical group 0.000 description 1
• 150000002926 oxygen Chemical group 0.000 description 1
• BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 1
• 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
• 229910052763 palladium Inorganic materials 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 229940049954 penicillin Drugs 0.000 description 1
• JRKICGRDRMAZLK-UHFFFAOYSA-L persulfate group Chemical group S(=O)(=O)([O-])OOS(=O)(=O)[O-] JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
• 229940124531 pharmaceutical excipient Drugs 0.000 description 1
• 239000012071 phase Substances 0.000 description 1
• 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 229940080469 phosphocellulose Drugs 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• 125000001557 phthalyl group Chemical group C(=O)(O)C1=C(C(=O)*)C=CC=C1 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
• JSPCTNUQYWIIOT-UHFFFAOYSA-N piperidine-1-carboxamide Chemical compound NC(=O)N1CCCCC1 JSPCTNUQYWIIOT-UHFFFAOYSA-N 0.000 description 1
• 125000005936 piperidyl group Chemical group 0.000 description 1
• 239000013612 plasmid Substances 0.000 description 1
• 229920000573 polyethylene Polymers 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 235000015320 potassium carbonate Nutrition 0.000 description 1
• 235000011181 potassium carbonates Nutrition 0.000 description 1
• 235000010333 potassium nitrate Nutrition 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 229960004618 prednisone Drugs 0.000 description 1
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
• 230000003449 preventive effect Effects 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• 229940072288 prograf Drugs 0.000 description 1
• 230000000770 proinflammatory effect Effects 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 235000019260 propionic acid Nutrition 0.000 description 1
• 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
• 125000003373 pyrazinyl group Chemical group 0.000 description 1
• 125000002755 pyrazolinyl group Chemical group 0.000 description 1
• LDIJKUBTLZTFRG-UHFFFAOYSA-N pyrazolo[1,5-a]pyrimidine Chemical class N1=CC=CN2N=CC=C21 LDIJKUBTLZTFRG-UHFFFAOYSA-N 0.000 description 1
• WFJZBOIOPMOUCB-UHFFFAOYSA-N pyridazine;hydrochloride Chemical compound Cl.C1=CC=NN=C1 WFJZBOIOPMOUCB-UHFFFAOYSA-N 0.000 description 1
• 125000006513 pyridinyl methyl group Chemical group 0.000 description 1
• 125000006085 pyrrolopyridyl group Chemical group 0.000 description 1
• IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
• 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
• 210000000664 rectum Anatomy 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 238000000611 regression analysis Methods 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
• 229960000371 rofecoxib Drugs 0.000 description 1
• HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 1
• 229950005741 rolipram Drugs 0.000 description 1
• 102220103281 rs878854716 Human genes 0.000 description 1
• 230000036573 scar formation Effects 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 238000012216 screening Methods 0.000 description 1
• 238000007789 sealing Methods 0.000 description 1
• 239000008299 semisolid dosage form Substances 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 229910001961 silver nitrate Inorganic materials 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 239000000661 sodium alginate Substances 0.000 description 1
• 235000010413 sodium alginate Nutrition 0.000 description 1
• 229940005550 sodium alginate Drugs 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 239000007909 solid dosage form Substances 0.000 description 1
• 230000003381 solubilizing effect Effects 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 125000003003 spiro group Chemical group 0.000 description 1
• 210000004988 splenocyte Anatomy 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 230000006641 stabilisation Effects 0.000 description 1
• 238000011105 stabilization Methods 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 229940032147 starch Drugs 0.000 description 1
• 238000010025 steaming Methods 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 230000035882 stress Effects 0.000 description 1
• 125000004426 substituted alkynyl group Chemical group 0.000 description 1
• 150000003890 succinate salts Chemical class 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 125000005864 sulfonamidyl group Chemical group 0.000 description 1
• 150000003871 sulfonates Chemical class 0.000 description 1
• 125000003375 sulfoxide group Chemical group 0.000 description 1
• 239000011593 sulfur Substances 0.000 description 1
• 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 239000011885 synergistic combination Substances 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 229940037128 systemic glucocorticoids Drugs 0.000 description 1
• 229960001967 tacrolimus Drugs 0.000 description 1
• QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
• 150000003892 tartrate salts Chemical class 0.000 description 1
• KYORUZMJUKHKFS-UHFFFAOYSA-N tert-butyl 4-aminobenzoate Chemical compound CC(C)(C)OC(=O)C1=CC=C(N)C=C1 KYORUZMJUKHKFS-UHFFFAOYSA-N 0.000 description 1
• VFEXTHJEPCYWPO-UHFFFAOYSA-N tert-butyl n-[4-(imidazo[1,2-b]pyridazin-8-ylamino)phenyl]carbamate Chemical compound C1=CC(NC(=O)OC(C)(C)C)=CC=C1NC1=CC=NN2C1=NC=C2 VFEXTHJEPCYWPO-UHFFFAOYSA-N 0.000 description 1
• 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 125000006092 tetrahydro-1,1-dioxothienyl group Chemical group 0.000 description 1
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
• 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
• 230000001225 therapeutic effect Effects 0.000 description 1
• 125000001113 thiadiazolyl group Chemical group 0.000 description 1
• 125000006090 thiamorpholinyl sulfone group Chemical group 0.000 description 1
• 125000006089 thiamorpholinyl sulfoxide group Chemical group 0.000 description 1
• 125000001984 thiazolidinyl group Chemical group 0.000 description 1
• 125000001544 thienyl group Chemical group 0.000 description 1
• 150000003567 thiocyanates Chemical class 0.000 description 1
• 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
• 210000001519 tissue Anatomy 0.000 description 1
• LBLYYCQCTBFVLH-UHFFFAOYSA-M toluenesulfonate group Chemical group C=1(C(=CC=CC1)S(=O)(=O)[O-])C LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
• 125000005490 tosylate group Chemical group 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
• 230000008733 trauma Effects 0.000 description 1
• 125000005270 trialkylamine group Chemical group 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical class CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
• 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
• DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
• 229940045145 uridine Drugs 0.000 description 1
• 208000019553 vascular disease Diseases 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 238000009736 wetting Methods 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
• 229910052725 zinc Inorganic materials 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1
• GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1